

# **Virginia Immunization Information System**

## ***HL7 – 2.4 & Real-time Transfer Specification***

**GTS Version 8.0.1**

Last Updated: March 28, 2012

|   |    |
|---|----|
| Introduction.....                                     | 4  |
| The Health Level Seven (HL7) Standard.....            | 4  |
| Scope of This Document.....                           | 4  |
| References.....                                       | 5  |
| HL7 Message Types Used in VIIS Transmissions.....     | 5  |
| ADT.....  | 5  |
| VXU.....  | 5  |
| ACK.....  | 5  |
| Message Segments: Field Specifications and Usage..... | 6  |
| HL7 Segment Structure.....                            | 6  |
| Rules for Sending Systems.....                        | 6  |
| ERR.....  | 7  |
| MSA.....  | 7  |
| MSH.....  | 8  |
| PID.....  | 9  |
| PD1.....  | 10 |
| NK1.....  | 10 |
| PV1.....  | 11 |
| RXA.....  | 11 |
| RXR.....  | 12 |
| OBX.....  | 12 |
| Batch Files of HL7 Messages.....                      | 14 |
| FHS.....  | 14 |
| FTS.....  | 14 |
| BHS.....  | 15 |
| BTS.....  | 15 |
| Real-time Processing.....                             | 20 |
| VXU^V04.....  | 20 |
| VXQ^V01.....  | 20 |
| VXR^V03.....  | 21 |
| VXX^V03.....  | 21 |
| ACK.....  | 21 |
| QCK.....  | 21 |
| MSH.....  | 21 |
| VXU^V04.....  | 22 |
| VXQ^V01.....  | 22 |
| QRD.....  | 22 |
| VXR segment detail.....                               | 24 |
| VXX^V03.....  | 24 |
| ACK.....  | 25 |
| MSA.....  | 26 |
| ERR.....  | 26 |
| QCK.....  | 26 |
| MSA.....  | 27 |
| QAK.....  | 27 |
| Appendix A -- HL7 Data Types.....                     | 28 |
| CE.....   | 28 |
| CM.....   | 28 |
| CX.....   | 28 |
| HD.....   | 29 |
| ID.....   | 29 |
| IS.....   | 29 |
| NM.....   | 29 |
| SI.....   | 29 |
| ST.....   | 29 |
| TS.....   | 29 |
| XAD.....  | 30 |
| XCN.....  | 31 |
| XPN.....  | 31 |
| XTN.....  | 31 |
| Appendix B -- HL7 Tables.....                         | 33 |
| Sex.....  | 34 |

|  |    |
|--|----|
| Event Type .....                                   | 34 |
| Patient class .....                                | 34 |
| Race.....  | 34 |
| Acknowledgment Code .....                          | 34 |
| Relationship.....                                  | 34 |
| Financial class .....                              | 35 |
| Message Type.....                                  | 35 |
| Observation result status codes .....              | 35 |
| Processing ID .....                                | 35 |
| Version ID.....                                    | 35 |
| Yes/No Indicator .....                             | 35 |
| Accept/Application Acknowledgment Conditions ..... | 35 |
| Route of Administration.....                       | 35 |
| Administrative Site.....                           | 35 |
| Ethnic Group .....                                 | 36 |
| Identifier Type.....                               | 36 |
| Nationality.....                                   | 36 |
| Publicity Code .....                               | 36 |
| Manufacturers of vaccines (code = MVX).....        | 36 |
| County/parish (Wisconsin only).....                | 37 |
| Immunization Information Source .....              | 40 |
| Substance Refusal Reason.....                      | 40 |
| Contraindications, Precautions.....                | 40 |
| Event Consequence .....                            | 43 |
| Patient Registry Status .....                      | 43 |
| Reaction Codes.....                                | 43 |
| Vaccine Group Code (WVGC) .....                    | 43 |
| Vaccine Trade Name (WVTN) .....                    | 44 |
| CPT Codes (WCPT) and CVX Codes (292) .....         | 47 |
| Trade Name .....                                   | 47 |

# Virginia Immunization Information System

## HL7 – 2.4 & Real-time Transfer Specification

### Introduction

The Virginia Immunization Information System (VIIS) has made available an interactive user interface on the World Wide Web for authorized users to enter, query and update client immunization records. The Web interface makes VIIS information and functions available on desktops around the state. However, some immunization providers already store and process similar data in their own information systems and may wish to keep using those systems while also participating in the statewide central repository. Others may have different billing needs and may decide they don't want to enter data into two diverse systems. VIIS has been enhanced to accept HL7 Version 2.4 for batch loads to submit client and immunization information to the VIIS. VIIS has also allows providers to submit client and immunization information using HL7 2.4 formatted VXQ^V01 Message (Query for Vaccination Record) and a VXU^V04 Message (Unsolicited Vaccination Update) and receive from VIIS the resulting HL7 2.4 Response Message in real time. Specifications for HL7 2.4 Real-time start on page 16.

### The Health Level Seven (HL7) Standard

The ANSI HL7 standard is widely used for data exchange in the health care industry. The full standard is quite lengthy, covering a variety of situations in patient care and health care finance and no single application is likely to use all of its content. The CDC has worked with HL7 developers to create a set of messages that permit exchange of immunization data. This document covers the subset of HL7 that will be used for client and immunization records exchanged between VIIS and outside systems.

- The basic unit transmitted in an HL7 implementation is the **message**.
- Messages are made up of several **segments**, each of which is one line of text, beginning with a three-letter code identifying the segment type.
- Segments are in turn made up of several **fields** separated by a delimiter character, “|”.

```
MSH|^~\&|VALLEY CLINIC^|VIIS^|19991005032342||VXU^V04|682299|P^|2.4^|||ER
PID||79928^|A5SMIT0071^|SMITH^MARY^T^|JOHNSON^|19951212|F
RXA|0|999|19970903|19970903|^90701^DTP^CPT
```

The details of how HL7 messages are put together, for VIIS purposes, will be explained later in this document. The example above shows the essentials of what a message looks like. In this example, a message is being sent on behalf of Valley Clinic to VIIS. The message consists of three segments. NOTE: Valley Clinic may or may not be the actual transmitter of the message. The transmitter of the message will be identified by VIIS from log-in information and not from an HL7 message.

- The Message Header segment (**MSH**) identifies the owner (**VALLEY CLINIC**) of the information being sent and the receiver (**VIIS**). It also identifies the message as being of type **VXU**. The **VXU** is an Unsolicited Vaccination Record Update, which is one of the message types defined by HL7.
- The Patient Identification segment (**PID**) gives the client's name (**MARY T SMITH**), birth date (**19951212**, in **YYYYMMDD** format), and other identifying fields.
- The Pharmacy Administration segment (**RXA**) tells that a DTP vaccine, with CPT code 90701, was administered on September 3, 1997 (formatted as 19970903). Many fields are optional and this example may have more information included in it. Some segments can be repeated within a single message. In this example, the message could have included a second **RXA** segment to record another immunization given.

HL7 does not specify how messages are transmitted. It is flexible enough to be used for both real-time interaction and large batches. The standard defines file header and file trailer segments that are used when a number of messages are gathered into a batch for transmission as a file. VIIS will use batch files of messages to communicate with outside systems.

### Scope of This Document

The General Transfer Specification (GTS) documented here supports automated exchange of data between the VIIS repository and outside systems. This allows both the client and immunization records to be available in both systems, so as to avoid the need to enter data twice. The remainder of this document specifies how HL7 file messages are constructed for the purposes of VIIS. It does not cover the methods that are used to transmit files between the VIIS central repository and outside systems. It covers only a small subset of the very extensive HL7 standard. Files of messages constructed from the guidelines in this document will fall within the HL7 standard, but there is a wide variety of other possible HL7 messages that are outside the scope of this document.

## References

- See Version 2.1 (September 2002) of the Health Level 7 standard for a full description of all messages, segments, and fields. Information regarding HL7 is at [www.hl7.org](http://www.hl7.org).
- The National Immunization Program within the Center for Disease Control ([www.cdc.gov/nip](http://www.cdc.gov/nip)) has published an Implementation Guide for Immunization Data with the purpose of keeping the use of HL7 for immunization data as uniform as possible.

## HL7 Message Types Used in VIIS Transmissions

VIIS uses three message types: ADT, VXU and ACK. The ADT is used for sending client data without any immunizations. The VXU is used for sending client data and immunizations. The ACK is used to acknowledge to the sender that a message has been received. The tables below show the segments that are used to construct each message type. Each segment is one line of text ending with the carriage return character. The carriage return is needed so that the HL7 messages are readable and printable. The messages may appear somewhat cryptic due to the scarcity of white space. (The standard has provisions for inclusion of binary data, but VIIS will not use these features.) Square brackets [ ] enclose optional segments and curly braces { } enclose segments that can be repeated; thus, an ADT message type could be composed of just MSH and PID segments. Also, any number of NK1 segments could be included in the message. The full HL7 standard allows additional segments within these message types, but they are unused by VIIS. In order to remain compliant with HL7, their use will not result in an error, but the recipient can ignore the content of the message. The segments that are documented here are sufficient to support the principal VIIS functions of storing data about clients and immunizations.

### ADT

Update Patient Information

|          |                                  |
|----------|----------------------------------|
| MSH      | Message Header                   |
| PID      | Patient Identification           |
| [{NK1}]  | Next of Kin / Associated Parties |
| [{*OBX}] | Observation/Result               |

### VXU

Unsolicited Vaccination Record Update

|         |   |
|---------|---|
| MSH     | Message Header  |
| PID     | Patient Identification                                    |
| [PD1]   | Patient Additional Demographic                            |
| [{NK1}] | Next of Kin / Associated Parties                          |
| [PV1]   | Patient Visit   |
| {RXA}   | Pharmacy / Treatment Administration                       |
| [RXR]   | Pharmacy / Treatment Route (Only one RXR per RXA segment) |
| [{OBX}] | Observation/Result*                                       |

### ACK

General Acknowledgment

|       |                        |
|-------|------------------------|
| MSH   | Message Header         |
| MSA   | Message Acknowledgment |
| [ERR] | Error                  |

\*The only OBX segment that is valid within an ADT message is one that specifies a CONTRAINDICATION in the OBX-03 Value Type field. (i.e., 30945-0^Contraindication^LN )

## RECOMMENDATIONS:

VIIS will NOT accept an ADT message (unsolicited demographic update) for a new client unless at least ONE immunization exists for that client in VIIS. Therefore, it is best to include the demographic information in a VXU message whenever possible, as this message type accommodates BOTH immunization information and demographic update information. If submitting a new client, using the ADT message, it must follow the VXU message for the new client within the file.

When a VXU^V04 (Unsolicited Vaccination Record Update) message type is sent with no RXA segment, a check is done to verify if the client exists in VIIS or not. If the client already exists in VIIS, then the demographic update will occur (\*if all other update business rules apply). If the client is new to VIIS, then the client will be rejected per current business rules.

## Message Segments: Field Specifications and Usage

### HL7 Segment Structure

Each segment consists of several fields that are separated by “|”, which is the field separator character. The tables below define how each segment is structured and contain the following columns:

- |                        |  |
|------------------------|--|
| 1. <b>SEQ</b>          | The ordinal position of the field in the segment. Since VIIS does not use all possible fields in the HL7 standard, these are not always consecutive.     |
| 2. <b>LEN</b>          | Maximum length of the field  |
| 3. <b>DT</b>           | HL7 data type of the field. See below for definition of HL7 data types.  |
| 4. <b>R/M</b>          | R means required by HL7, and M means mandatory for VIIS. Blank indicates an optional field.  |
| 5. <b>RP/#</b>         | Y means the field may be repeated any number of times, an integer gives the maximum number of repetitions, and a blank means no repetition is permitted. |
| 6. <b>TBL#</b>         | Number of the table giving valid values for the field.   |
| 7. <b>ELEMENT NAME</b> | HL7 name for the field.  |
- **HL7 data types.** Each field has an HL7 data type. Appendix A of this document lists and defines the HL7 data types needed for VIIS. The elemental data types Numeric (NM) and String (ST) consist of one value, while some data types, such as Extended Person Name (XPN) are composites.
  - **Delimiter characters.** Field values of composite data types consist of several components separated by the **component separator**, “^”. When components are further divided into sub-components, these are separated by the **sub-component separator**, “&”. Some fields are defined to permit repetition separated by the **repetition character**, “~”. When these special characters need to be included within text data, their special interpretations are prevented by preceding them with the **escape character**, “\”.

```
MSH|^~\&| .....
XXX|field1|component1^component2^subcomponent3.1&subcomponent3.2^component4| .....
YYY|repetition1~repetition2| .....
ZZZ|data includes escaped \|~ special characters| .....
```

In the example above, the Message Header segment uses the field separator, “|”, immediately after the “MSH” code that identifies the segment. This establishes what character serves as the field separator throughout the message. The next field, the four characters “^~\&”, establishes, in order, the component separator character, the repetition character, the escape character, and the sub-component separator character that will apply throughout the message. The hypothetical “XXX” segment includes field1 with no internal structure, but the next field has several components separated by “^”, and the third of these is made up of two sub-components separated by “&”. The hypothetical “YYY” segment’s first field permits repetition, in this example the two values “repetition1” and “repetition2”. The hypothetical “ZZZ” segment’s field has a text value that includes the characters “|~”, and these are escaped to prevent their normal structural interpretation.

In VIIS, sub-components, repetition and text values requiring the escape character will be rare. Components within fields are common, since names and addresses are represented this way. HL7 permits the use of other delimiters besides the recommended ones and the delimiters used in each message are given in the Message Header segment. VIIS will always use the recommended delimiters when sending files and requires their use for files received.

### Rules for Sending Systems

The following rules are used by sending systems to construct HL7 messages.

- Encode each segment in the order specified in the message format.
- Begin the segment with the 3-letter segment ID (for example RXA).
- Precede each field with the data field separator (“|”).
- Use HL7 recommended encoding characters (“^~\&”).
- Encode the data fields in the order given in the table defining segment structure.
- Encode the data field according to its HL7 data type format.
- Do not include any characters for fields not present in the segment. Since later fields in the segment are encoded by ordinal position, fields that are not present do not reduce the number of field separators in the segment. For example, when the second and third fields are not present, the field separators maintain the ordinal position of the fourth field: |field1|||field4
- Data fields that are present but explicitly null are represented by empty double quotes “”.
- Trailing separators may optionally be omitted. For example, |field1|field2||| is equivalent to |field1|field2, when field3 and subsequent fields are not present.

- End each segment with the segment terminator (always the carriage return character, ASCII hex 0D).

**The following rules are used by receiving systems to process HL7 messages.**

- Treat data segments that are expected but not present as if all data fields in the segment were not present.
- Require use of HL7 recommended Field Separator |, and Encoding characters ^~\& for encoding messages.
- Ignore any data segment that is included but not expected, rather than treating it as an error. The HL7 message types used by VIIS may include many segments besides the ones in this document, and VIIS ignores them. VIIS will not send messages with segments not documented in this specification, but reserves the right to specify more segments at a later date. The rule to ignore unexpected segments facilitates this kind of change.
- Ignore data fields found but not expected within a segment.

The message segments below are needed to construct message types that are used by VIIS. Each segment is given a brief description excerpted from the HL7 standard. The tables define what fields make up each segment. Since VIIS does not use all the fields that HL7 defines, there are sometimes gaps in the ordinal sequence of fields. Following HL7 rules, the gaps do not diminish the number of field separators within the segment. For example, if the second and third fields in a segment are not present, their field separators remain in order to indicate that the next field present is the fourth: field1|||field4 .

## ERR

The ERR segment is used to add error comments to acknowledgment messages.

| SEQ | LEN | DT | R/M | RP/# | TBL# | ELEMENT NAME            |
|-----|-----|----|-----|------|------|-------------------------|
| 1   | 80  | CM | R   | Y    |      | Error Code and Location |

### Field Notes:

ERR-1 A composite field with four components.

<segment ID (ST)>^<sequence (NM)>^<field position (NM)>^<field component ordinal number (NM)>

The first component identifies the segment ID containing the error. The second component identifies the input file line number of the segment containing the error. The third component identifies by ordinal number the field containing the error. The fourth component identifies, by ordinal number, the field component containing the error (0 is used if not applicable) The remaining five components of the CE data type are not valued and their '^' separators are not generated. Note that error text is transmitted in field MSA-3. For example, if the NK1 segment is missing a mandatory field:

ERR|NK1^10^2^1

This error message identifies the NK1 segment occurring on line 10 of the input file whose mandatory second field (Name) is missing the mandatory 1<sup>st</sup> component (Family Name).

## MSA

The MSA segment contains information sent while acknowledging another message.

| SEQ | LEN | DT | R/M | RP/# | TBL# | ELEMENT NAME        |
|-----|-----|----|-----|------|------|---------------------|
| 1   | 2   | ID | R   |      | 0008 | Acknowledgment Code |
| 2   | 20  | ST | R   |      |      | Message Control ID  |
| 3   | 80  | ST |     |      |      | Text Message        |

### Field Notes:

- MSA-1 Acknowledgement code giving receiver's response to a message. AA (Application Accept) means the message was processed normally. AE (Application Error) means an error prevented normal processing. An error message will be put in MSA-3, and for ACK messages the optional ERR segment will be included.
- MSA-2 The message control ID from MSH-10 in the message being acknowledged. This allows the sending system to associate this response with the message being responded to.
- MSA-3 Text of error message, used when MSA-1 does not have the normal value of AA.

**MSH**

The MSH segment defines the intent, source, destination and some specifics of the syntax of a message.

| SEQ | LEN | DT  | R/M | RP/# | TBL# | ELEMENT NAME               |
|-----|-----|-----|-----|------|------|----------------------------|
| 1   | 1   | ST  | R   |      |      | Field Separator            |
| 2   | 4   | ST  | R   |      |      | Encoding Characters        |
| 3   | 180 | HD  |     |      |      | Sending Application        |
| 4   | 180 | HD  |     |      |      | Sending Facility           |
| 5   | 180 | HD  |     |      |      | Receiving Application      |
| 6   | 180 | HD  |     |      |      | Receiving Facility         |
| 7   | 26  | TS  |     |      |      | Date/Time Of Message       |
| 9   | 7   | CM  | R   |      |      | Message Type               |
| 10  | 20  | ST  | R   |      |      | Message Control ID         |
| 11  | 3   | PT  | R   |      | 0103 | Processing ID              |
| 12  | 60  | VID | R   |      | 0104 | Version ID                 |
| 15  | 2   | ID  |     |      | 0155 | Accept Acknowledgment Type |

**Field Notes:**

- MSH-1 Determines the field separator in effect for the rest of this message. VIIS requires the HL7 recommended field separator of “|”.
- MSH-2 Determines the component separator, repetition separator, escape character, and sub-component separator in effect for the rest of this message. VIIS requires the HL7 recommended values of ^~\&.
- MSH-3 Name of the sending application. When sending, VIIS will use “VIIS” followed by the current version number of the registry. This field is an optional convenience. See MSH-4 and MSH-6 for the fields principally used to identify sender and receiver of the message.
- MSH-4 Identifies for whom the message is being sent (the owner of the message information). When sending, VIIS will use “VIIS”. When the message is being sent to VIIS and the Provider Organization owning the information is different than the organization transmitting the message, use either the VIIS Provider ID of the Provider Organization that owns the information preceded by a component separator (e.g., ^36^ ) or the short Provider Organization name (e.g., VIIS^ ). Contact the VIIS Help Desk for the appropriate organization ID. If the owner of the information and the transmitter of the information are the same Provider Organization, this field can be left blank.
- MSH-6 Identifies the message receiver. When sending, VIIS will use the short Provider Organization name assigned when the provider first registers with the VIIS database and VIIS-Web interface.
- MSH-7 Date and time the message was created. VIIS ignores any time component. See the TS data type.
- MSH-9 This is a required field. Two components of this field give the HL7 message type (see Table 0076) and the HL7 triggering event (see Table 0003). Within HL7, the triggering event is considered to be the real-world circumstance causing the message to be sent. For VIIS purposes, this field should have the value ADT^A31 for a message conveying client information or the value VXU^V04 for a message conveying client and immunization information. In acknowledgement messages the value ACK is sufficient and the second component may be omitted.
- MSH-10 This is a required field. Message rejection will result if nothing is received in this field. The message control ID is a string (which may be a number) uniquely identifying the message among all those ever sent by the sending system. It is assigned by the sending system and echoed back in the ACK message sent in response.
- MSH-11 The processing ID to be used by VIIS is **P** for production processing. If this field is null, an informational message is generated indicating that VIIS is defaulting to **P**.
- MSH-12 This is a required field. For the parser, the version number that is read in the first MSH segment, of the file, will be the version assumed for the whole file. For example, use a value of “2.3.1” to indicate HL7 Version 2.3.1 or “2.4” to indicate HL7 Version 2.4. If there is no version number found in the first MSH segment, a hard error will occur and the file will not be processed.  
**\*\*For VIIS to PO providers, the Exchange Data screen will need to be set to the version number that the organization has selected, in which to receive their data files. Setting the version number “tells” the writer which HL7 version format to use when generating the file in (the default will be the most recent version).**
- MSH-15 This field controls whether an acknowledgement is generated for the message sent. VIIS suggests a value of ER to ask that acknowledgements be sent only for messages that cannot be processed normally. If the field is empty, VIIS will assume the value of ER.



**PID**

The PID segment is used by all applications as the primary means of communicating patient identification information. This segment contains permanent patient identifying and demographic information that, for the most part, is not likely to change frequently.

| SEQ | LEN | DT  | R/M | RP/# | TBL# | ELEMENT NAME                |
|-----|-----|-----|-----|------|------|-----------------------------|
| 3   | 20  | CX  | R   | Y    | 0203 | Patient ID (Internal ID)    |
| 5   | 48  | XPN | R   | Y    |      | Patient Name                |
| 6   | 48  | XPN |     | Y    |      | Mother's Maiden Name        |
| 7   | 26  | TS  | M   |      |      | Date/Time of Birth          |
| 8   | 1   | IS  |     |      | 0001 | Sex                         |
| 10  | 80  | CE  |     | Y    | 0005 | Race                        |
| 11  | 106 | XAD |     | Y    |      | Patient Address             |
| 13  | 40  | XTN |     |      |      | Phone number – home         |
| 19  | 16  | ST  |     |      |      | SSN Number – Patient        |
| 22  | 80  | CE  |     | Y    | 0189 | Ethnic Group                |
| 24  | 1   | ID  |     |      | 0136 | Multiple Birth Indicator    |
| 25  | 2   | NM  |     |      |      | Birth Order                 |
| 29  | 26  | TS  |     |      |      | Patient Death Date and Time |

**Field Notes:**

- PID-3 Sub-components 1 (ID) and 5 (identifier type code) are required in the PID-3 field. When a Provider Organization is sending to VIIS, use the sending system's Chart Number or other identifier if available. When VIIS is sending to an outside system it will use the client's VIIS ID and chart number when it is available.
- PID-5 See the XPN data type. Last name and first name are required in the first two components. If the Name Type Code component is included, use L-Legal **NOTE: If client does not have a first name, NO FIRST NAME must be entered.** VIIS does not support repetition of this field.
- PID-6 See the XPN data type. In this context, where the mother's name is used for client identification, VIIS uses only last name and first name. A mother's legal name might also appear in the context of an NK1 segment. VIIS does not support repetition of this field.
- PID-7 Give the year, month, and day of birth (YYYYMMDD). VIIS ignores any time component.
- PID-8 See Table 0001. Use F, M, or U.
- PID-10 See Table 0005. VIIS stores and writes "Unknown" values as null. VIIS does not support repetition of this field.
- PID-11 See the XAD data type. VIIS does not support repetition of this field.
- PID-13 See the XTN data type. Version 2.4 includes the support of the N, X, B and C sequences. VIIS does not support repetition of this field. If PRN is specified in component 2 (telecommunication use code (ID) from table 0201) VIIS will use the 6<sup>th</sup> 7<sup>th</sup> 8<sup>th</sup> and 9<sup>th</sup> components for specification of area code, phone number, extension and text, respectively. Otherwise, VIIS will assume that the phone number is specified in the first component in the [NNN] [(999)]999-9999[X99999][B99999][C any text] format
- PID-19 NOTE: Social security number is used for identification purposes only, and is not displayed in screens or distributed to Provider Organizations. Support of PID-19 is for backwards compatibility only. VIIS recommends its specification in PID-03.
- PID-22 See Table 0189. VIIS stores and writes "Unknown" values as null. VIIS supports repetition of this field.
- PID-24 Use Y to indicate that the client was born in a multiple birth.
- PID-25 Relevant when client was born in a multiple birth. Use 1 for the first born, 2 for the second, etc. This field is useful in matching client data to existing records.
- PID-29 The date of death, if client is deceased. Give the year, month, and day (YYYYMMDD). VIIS ignores any time component. If a death date is sent, then the Patient Registry Status in PD1-14 must indicate a value of "P" for permanently inactive/deceased.

**PD1**

The PD1 carries patient additional demographic information that is likely to change.

| SEQ | LEN | DT  | R/M | RP/# | TBL# | ELEMENT NAME                                |
|-----|-----|-----|-----|------|------|---|
| 11  | 80  | CE  |     |      | 0215 | Publicity Code                              |
| 12  | 1   | ID  |     |      | 0136 | Protection Indicator                        |
| 13  | 8   | DT  |     |      |      | Protection Indicator effective date         |
| 14  | 250 | XON |     |      |      | Place of Worship                            |
| 15  | 250 | CE  |     |      |      | Advance directive code                      |
| 16  | 1   | IS  |     |      | 0441 | Immunization registry status                |
| 17  | 8   | DT  |     |      |      | Immunization registry status effective date |
| 18  | 8   | DT  |     |      |      | Publicity Code effective date               |

**Field Notes:**

PD1-11 Controls whether recall/reminder notices are sent. VIIS will recognize “01” to indicate no recall/reminder notices or “02” recall/reminder notices any method.

PD1-12 Controls visibility of records to other organizations. Indicates whether or not consent has been given (or assumed) for record sharing. Three values include: **Null** – patient/guardian has not yet been asked to give consent to share or has not responded, **Y** – sharing is allowed and **N**- sharing is not allowed.

PD1-13 Effective date for protection indicator reported in PD1-12. Format is YYYYMMDD.

PD1-16 Identifies the registry status of the patient. See table 0441.

PD1-17 Effective date for registry status reported in PD1-16. Format is YYYYMMDD.

PD1-18 Effective date for publicity code reported in PD1-11. Format is YYYYMMDD.

**NK1**

The NK1 segment contains information about the patient’s other related parties. Any associated parties may be identified. Utilizing *NK1-1-set ID*, multiple NK1 segments can be sent to patient accounts.

| SEQ | LEN | DT  | R/M | RP/# | TBL# | ELEMENT NAME |
|-----|-----|-----|-----|------|------|--------------|
| 1   | 4   | SI  | R   |      |      | Set ID - NK1 |
| 2   | 48  | XPN |     | Y    |      | Name         |
| 3   | 60  | CE  |     |      | 0063 | Relationship |
| 4   | 106 | XAD |     | Y    |      | Address      |
| 5   | 40  | XTN |     | Y    |      | Phone Number |

**Field Notes:**

NK1-1 Sequential numbers. Use “1” for the first NK1 within the message, “2” for the second, and so forth. Although this field is required by HL7, VIIS will ignore its value, and there is no requirement that the record for the same responsible person keep the same sequence number across multiple messages, in the case that information from the same record is transmitted more than once.

NK1-2 Name of the responsible person who cares for the client. See the XPN data type. VIIS does not support repetition of this field.

NK1-3 Relationship of the responsible person to the client. See data type CE and Table 0063 in the HL7 tables. Use the first three components of the CE data type, for example IMTH^Mother^HL70063|.

NK1-4 Responsible person’s mailing address. See the XAD data type. VIIS does not support repetition of this field.

NK1-5 Responsible person’s phone number. VIIS does not support repetition of this field. If PRN is specified in component 2 (telecommunication use code (ID) from table 0201) VIIS will use the 6<sup>th</sup> 7<sup>th</sup> 8<sup>th</sup> and 9<sup>th</sup> components for specification of area code, phone number, extension and text, respectively. Otherwise, VIIS will assume that the phone number is specified in the first component in the [NNN] [(999)]999-9999[X99999][B99999][C any text] format.

**PV1**

The PV1 segment is used to send visit-specific information.

| SEQ | LEN | DT | R/M | RP/# | TBL# | ELEMENT NAME    |
|-----|-----|----|-----|------|------|-----------------|
| 2   | 1   | IS | R   |      | 0004 | Patient Class   |
| 20  | 50  | FC | M   | Y    | 0064 | Financial Class |

**Field Notes:**

PV1-2 See table 0004. VIIS will store and write a value of “R” (recurring patient) for this field.

PV1-20 See table 0064. VIIS defines this field as a required field. If an invalid financial class or date format is received, an INFORMATIONAL error message is generated. The entire message is NOT rejected, as this is an optional HL7 segment.

**Example:**

FHS|^~\&||VIIS|||200810140632||immun.dat||IMM

BHS|^~\&||VIIS|||200810140632|||

MSH|^~\&||VIIS|||VXU^V04|2008101406322000351956|T|2.3.1

PID|||Chart123^^^^PI^~1234567^^^^SR^||Lastname^Firstname^MI^|^^^^|20060101|F|^^^^|123 MAIN

ST^MADISON^WI^53713^USA^|((608)555-1212|)|^|

NK1|||Lastname^Firstname^MI^|SEL^SELF^HL70063^|123 MAIN ST^MADISON^WI^53713^USA^|((608)555-1212^|

**PV1||R|||||||||V04^20061017~V03^20071202**

RXA|0|999|20061017|20061017|^90748^HepB-Hib^CPT|0||01^|

RXA|0|999|20031202|20071202|^90656^Preservative-Free

Influenza^CPT|0.50|ML||00^|^ClinicianLast^ClinicianFirst^|Clinic^|Lot

Number||EVN^Evans Medical Limited^MVX^|

BTS|||

FTS|||

**RXA**

The RXA carries pharmacy administration data. It is a repeating segment and can record unlimited numbers of vaccinations.

| SEQ | LEN | DT  | R/M | RP/# | TBL#   | ELEMENT NAME                      |
|-----|-----|-----|-----|------|--------|-----------------------------------|
| 1   | 4   | NM  | R   |      |        | Give Sub-ID Counter               |
| 2   | 4   | NM  | R   |      |        | Administration Sub-ID Counter     |
| 3   | 26  | TS  | R   |      |        | Date/Time Start of Administration |
| 4   | 26  | TS  | R   |      |        | Date/Time End of Administration   |
| 5   | 100 | CE  | R   |      |        | Administered Code                 |
| 6   | 20  | NM  | R   |      |        | Administered Amount               |
| 9   | 200 | CE  |     | Y    | NIP001 | Administration Notes              |
| 10  | 200 | XCN |     | Y    |        | Administering Provider            |
| 11  | 200 | CM  |     |      |        | Administered-at location          |
| 15  | 20  | ST  |     | Y    |        | Substance Lot Number              |
| 17  | 60  | CE  |     | Y    | 0227   | Substance Manufacturer Name       |
| 18  | 200 | CE  |     | Y    | NIP002 | Substance Refusal Reason          |

**Field Notes:**

RXA-1 Required by HL7. Use “0” for VIIS.

RXA-2 Required by HL7. Use “999” for VIIS

RXA-3 Date the vaccine was given. VIIS ignores any time component.

RXA-4 Required by HL7. Ignored by VIIS, which will use the value in RXA-3.

RXA-5 This field identifies the vaccine administered. VIIS accepts the CVX code, CPT code, Vaccine Trade Name, or Vaccine Group Code for the vaccine administered. If using the CVX code, give the CVX code in the first component and “CVX” in the third component. If using the CPT code, the vaccine group code or vaccine trade name, use components four through six. For example, give the CPT code in the fourth component and “CPT” in the sixth component, |^^90700^DtaP^CPT|. If using vaccine group code, use “WVGC” as the name of the coding system. If using vaccine trade name, use “WVTN” as the name of the coding system. See the CE data type and HL7 - Table

0292 (CVX Codes), VIIS – Table WCPT (CPT Codes), VIIS – Table WVGC (Vaccine Group Codes), and VIIS – Table WVTN (Vaccine Trade Names).

RXA-6 This field identifies the dose magnitude. Although a required field by HL7 and VIIS, VIIS ignores the incoming value and stores a value of 1.

RXA-9 VIIS will recognize 00 to indicate Administered Vaccine or 01 to indicate Historical Record. When sending, VIIS will include the corresponding immunization id in the second repeating segment.

|01^^^^~9999999^VIIS immunization id^IMM\_ID^^|

RXA-10 Identifies the name of the person physically administering the vaccine (the vaccinator). VIIS will use components 2 – 7 to record the name and does not support repetition of this field.

RXA-11 VIIS will use this field to identify the facility where the vaccine was administered. Place the facility name in component 4.

RXA-15 Manufacturer's lot number for the vaccine. VIIS does not support repetition of this field.

RXA-17 Vaccine manufacturer from Table 0227, for example |AB^Abbott^ MVX^^|. The HL7 2.4 specification recommends use of the external code set MVX. "When using this code system to identify vaccines, the coding system component of the CE field should be valued as "MVX" not as "HL70227." VIIS does not support repetition of this field.

RXA-18 When applicable, this field records the reason the patient refused the vaccine. See table NIP002. Any entry in this field indicates that the patient did not take the substance. The vaccine that was offered should be recorded in RXA-5, with the number 0 recorded for the dose number in RXA-2. Do not record contraindications, immunities or reactions in this field. VIIS does not support repetition of this field.

**NOTE:** VIIS only stores that a refusal of a vaccine occurred, not a specific type of refusal, so all outgoing refusals will default to "parental refusal" and will be returned in a separate VXU message.

## RXR

The Pharmacy/Treatment Route Segment contains the alternative combination of route and site.

| SEQ | LEN | DT | R/M | RP/# | TBL# | ELEMENT NAME |
|-----|-----|----|-----|------|------|--------------|
| 1   | 60  | CE | R   |      | 0162 | Route        |
| 2   | 60  | CE |     |      | 0163 | Site         |

### Field Notes:

RXR-1 This is the route of administration from table 0162.

RXR-2 This is the site of the route of administration from table 0163.

## OBX

The Observation/Result Segment is used to transmit an observation.

| SEQ | LEN   | DT | R/M | RP/# | TBL# | ELEMENT NAME                 |
|-----|-------|----|-----|------|------|------------------------------|
| 1   | 4     | SI |     |      |      | Set ID-OBX                   |
| 2   | 3     | ID |     |      |      | Value type                   |
| 3   | 80    | CE | R   |      |      | Observation Identifier       |
| 5   | 65536 | -  | M   | Y    |      | Observation Value            |
| 11  | 1     | ID | R   |      | 0085 | Observation Result Status    |
| 14  | 26    | TS |     |      |      | Date/Time of the observation |

**Field Notes:**

- OBX-1 Sequential numbers. Use “1” for the first OBX within the message, “2” for the second, and so forth. For Vaccine Due Next recommendation, the set ID will be the same value for each of the three OBX segments comprising the recommended vaccine.
- OBX-2 Use CE for VIIS.
- OBX-3 When indicating a **Vaccination Contraindication/Precaution**, use 30945-0 in this field and enter a Contraindication, Precaution, or Immunity code (NIP004) in OBX-5.  
Example: OBX|1|CE|30945-0^Contraindication^LN||21^acute illness^NIP^^^|||||F|

When indicating a **Reaction to Immunization**, use 31044-1 in this field and enter a Reaction code (VIIS001) in OBX-5.

Example: OBX|1|CE|31044-1^Reaction^LN||HYPOTON^hypotonic^VIIS^^^|||||F|

When indicating a **Vaccination Adverse Event Outcome**, use 30948-4 in this field and enter an Event Consequence code (NIP005) in OBX-5.

Example: OBX|1|CE|30948-4^Adverse Outcome^LN||E^er room^NIP^^^|||||F|

- OBX-5 Text reporting Contraindication, Precaution, or Immunity (NIP004), Reaction (VIIS001), or Event Consequence (NIP005). VIIS has imposed a CE data type upon this field. The first component of which is required.  
(e.g., |PERTCONT^Pertussis contra^VIIS^^^|)

OBX-11 Required for HL7. Use “F” for VIIS.

OBX-14 Records the time of the observation. VIIS ignores any time component.

**NOTE 1:** The only valid OBX Observation Identifier (OBX-03) for an **ADT^A31** message type is Contraindication/Precaution (30945-0).

**NOTE 2:** All OBX messages with an observation identifier of Vaccination Contraindication/Precaution will be returned in an outgoing file in a separate ADT message for the client.

## Batch Files of HL7 Messages

The definitions above tell how to create messages containing client and immunization data. Each message can logically stand on its own and HL7 is compatible with various methods of online and batch transmission. VIIS uses batch files to transmit many messages together. HL7 provides special header and footer segments to structure batch files. These segments are not part of any message, but serve to bracket the messages defined above. The structure of a batch file is as follows.

```

FHS                (file header segment)
{ BHS              (batch header segment)
  { [MSH           (zero or more HL7 messages)
    ....
    ....
    ....
  } }
  BTS              (batch trailer segment)
}
FTS                (file trailer segment)

```

### FHS

#### File Header Segment

The FHS segment is used to head a file (group of batches).

| SEQ | LEN | DT | R/M | RP/# | TBL# | ELEMENT NAME              |
|-----|-----|----|-----|------|------|---------------------------|
| 1   | 1   | ST | R   |      |      | File Field Separator      |
| 2   | 4   | ST | R   |      |      | File Encoding Characters  |
| 3   | 15  | ST |     |      |      | File Sending Application  |
| 4   | 20  | ST | M   |      |      | File Sending Facility     |
| 6   | 20  | ST | M   |      |      | File Receiving Facility   |
| 7   | 26  | TS | M   |      |      | File Creation Date/Time   |
| 9   | 20  | ST | M   |      |      | File Name/ID              |
| 10  | 80  | ST |     |      |      | File Header Comment       |
| 11  | 20  | ST | M   |      |      | File Control ID           |
| 12  | 20  | ST |     |      |      | Reference File Control ID |

#### **Field Notes:**

FHS-1 Same definition as the corresponding field in the MSH segment.

FHS-2 Same definition as the corresponding field in the MSH segment.

FHS-3 Same definition as the corresponding field in the MSH segment.

FHS-4 Same definition as the corresponding field in the MSH segment.

FHS-6 Same definition as the corresponding field in the MSH segment.

FHS-7 Same definition as the corresponding field in the MSH segment.

FHS-9 Name of the file as transmitted from the initiating system.

FHS-10 Free text, which may be included for convenience, but has no effect on processing.

FHS-11 This field is used to identify a particular file uniquely among all files sent from the sending facility identified in FHS-4.

FHS-12 Contains the value of FHS-11-file control ID when this file was originally transmitted. Not present if this file is being transmitted for the first time.

### FTS

#### File Trailer Segment

The FTS segment defines the end of a file.

| SEQ | LEN | DT | R/M | RP/# | TBL# | ELEMENT NAME         |
|-----|-----|----|-----|------|------|----------------------|
| 1   | 10  | NM | M   |      |      | File Batch Count     |
| 2   | 80  | ST |     |      |      | File Trailer Comment |

#### **Field Notes:**

FTS-1 The number of batches contained in this file. VIIS normally sends one batch per file and discourages sending multiple batches per file.

FTS-2 Free text, which may be included for convenience, but has no effect on processing.

**BHS**

## Batch Header Segment

The BHS segment defines the start of a batch.

| SEQ | LEN | DT | R/M | RP/# | TBL# | ELEMENT NAME               |
|-----|-----|----|-----|------|------|----------------------------|
| 1   | 1   | ST | R   |      |      | Batch Field Separator      |
| 2   | 4   | ST | R   |      |      | Batch Encoding Characters  |
| 3   | 15  | ST |     |      |      | Batch Sending Application  |
| 4   | 20  | ST | M   |      |      | Batch Sending Facility     |
| 6   | 20  | ST | M   |      |      | Batch Receiving Facility   |
| 7   | 26  | TS | M   |      |      | Batch Creation Date/Time   |
| 10  | 80  | ST |     |      |      | Batch Comment              |
| 11  | 20  | ST | M   |      |      | Batch Control ID           |
| 12  | 20  | ST |     |      |      | Reference Batch Control ID |

**Field Notes:**

- BHS-1 This field contains the separator between the segment ID and the first real field, *BHS-2-batch encoding characters*. As such it serves as the separator and defines the character to be used as a separator for the rest of the segment. VIIS requires | (ASCII 124).
- BHS-2 This field contains the four characters in the following order: the component separator, repetition separator, escape characters and sub-component separator. VIIS requires ^~\&, (ASCII 94, 126, 92 and 38 respectively).
- BHS-3 Same definition as the corresponding field in the MSH segment.
- BHS-4 Same definition as the corresponding field in the MSH segment.
- BHS-6 Same definition as the corresponding field in the MSH segment.
- BHS-7 Same definition as the corresponding field in the MSH segment.
- BHS-10 Free text, which may be included for convenience, but has no effect on processing.
- BHS-11 This field is used to uniquely identify a particular batch. It can be echoed back in *BHS-12-reference batch control ID* if an answering batch is needed. For VIIS purposes, the answering batch will contain ACK messages.
- BHS-12 This field contains the value of *BHS-11-batch control ID* when this batch was originally transmitted. Not present if this batch is being sent for the first time. See definition for *BHS-11-batch control ID*.

**BTS**

## Batch Trailer Segment

The BTS segment defines the end of a batch.

| SEQ | LEN | DT | R/M | RP/# | TBL# | ELEMENT NAME        |
|-----|-----|----|-----|------|------|---------------------|
| 1   | 10  | ST | M   |      |      | Batch Message Count |
| 2   | 80  | ST |     |      |      | Batch Comment       |

**Field Notes:**

- BTS-1 This field contains the count of the individual messages contained within the batch.
- BTS-2 Free text, which can be included for convenience, has no effect on processing.

## File Interchange between VIIS and Outside Systems

The central repository of VIIS contains records of clients from around the state. Client and immunization records flow both ways between VIIS and outside systems. Data, for a particular client, is transmitted by VIIS to an outside system (Provider Organization) only if the client is identified as having a relationship with that Organization AND the relationship was created by transmitting the client's record to VIIS. So, an exchange of information about a given client is always initiated by the outside system. There are three options for exchanging data with VIIS:

- (1) The Provider Organization can send data to VIIS and request that no data is returned from VIIS.
- (2) The Provider Organization can request data from VIIS while not providing data to VIIS.
- (3) The Provider Organization can send data to VIIS and VIIS will return any updated information regarding the clients that have a relationship with that Provider Organization.

Note: client and immunization data can also be entered, queried, and modified using the VIIS-Web interface. This provides an alternate way of identifying a client as having a relationship with a Provider Organization. The use of VIIS-Web is not required to create a relationship between a Provider Organization and a client. The first transmission to VIIS, for a client immunization record, will create the link that will cause VIIS to transmit that client's record to the outside system.

HL7 messages are always part of a two-way exchange between an initiating system and a responder. Sometimes the initial message implies specific data to be sent in a response. Other times, as is the case with VIIS client and immunization data, the principal response of the receiving system is to process the message and post whatever it contains to its own database. For these cases, HL7 provides the ACK message type, which contains no new application data, but allows the receiver to inform the initiator that the message has been received and processed successfully. If an error prevents successful processing, optional parts of the ACK message will allow this to be communicated as well.

For exchanges between VIIS and outside systems, it is the responsibility of the outside system to initiate the transfer of the first file, containing ADT and/or VXU messages with client and immunization data. After processing those messages, VIIS responds with a file of ACK messages. At the same time or soon after, VIIS also creates another file of ADT and VXU messages, containing the full client record, to send to the Provider Organization that initiated the first transfer. It is the responsibility of that Organization as receiver to transmit back a file of ACK messages. During this second exchange, in terms used by HL7, VIIS is the initiator and the outside system is the respondent. However, it is the receipt of the first file initiated by the outside system that causes VIIS to initiate sending its own data file.

| Provider Organization |   | VIIS  |   |
|-----------------------|---|---|---|
|                       |   | Outgoing  | Receiving   |
| 1.                    | Creates a file of client and immunization records that have changed since they were last transmitted to VIIS. |   |   |
| 2.                    | Transmits the file to VIIS.   |   |   |
| 3.                    |   |   | Processes the file received, creates a file of ACK messages.        |
| 4.                    |   | Transmits the ACK file back to the initiator of the original file.  |   |
| 5.                    | Processes the ACK file to confirm success of the file transmission.   |   |   |
| 6.                    |   | Creates a file of client and immunization records that have changed since they were last transmitted to this Provider Organization. |   |
| 7.                    |   | Transmits this file to the Provider Organization.   |   |
| 8.                    | Processes the file received, creates a file of ACK messages.  |   |   |
| 9.                    | Transmits the ACK file back to VIIS   |   |   |
| 10.                   |   |   | Processes the ACK file to confirm success of the file transmission. |

The 15<sup>th</sup> field, in the MSH message header segment, allows the initiator to ask that the message be acknowledged only in the case of an error and VIIS supports this in order to minimize the number of ACK messages transmitted. In this case, the ACK file contains only error messages (an optional form of the ACK message type). The original messages, with no answering error messages, are implicitly acknowledged as successfully processed. If all messages in a batch are successful, the answering ACK file will only contain file batch headers and footers, with no actual ACK messages. For Step, in the above table, it is



permissible for a Provider Organization to send a file containing only file batch headers and footers as a way of triggering the file that VIIS creates in Step 6. It is also possible that the file, VIIS creates in Step 6, will contain only file batch headers and footers if there are no records to send.

## Examples

To illustrate how a VIIS HL7 file is put together we will document how the fictional organization, Valley Clinic, formats client and immunization records to be transmitted to VIIS. The following table displays the information to be transmitted and it is organized into HL7 segments and fields. For example, PID-3 refers to the third field in the Patient Identification segment.

| Information to transmit  | Data value to be entered                                       | HL7 Format  |
|--|--|-------------|
| • Client #1  |  | PID segment |
| • Chart Number (ID on Valley Clinic's system)                      | 45LR999  | PID-3       |
| • Name   | GEORGE M MILLER JR   | PID-5       |
| • Mother's maiden name   | MARTHA OLSON   | PID-6       |
| • Birth date   | February 27, 1995  | PID-7       |
| • Sex  | M  | PID-8       |
| • Address  | 123 MAIN ST<br>MADISON, WI 53000, WI025                        | PID-11      |
| • Social Security Number   | 000111222  | PID-19      |
| • Birth Place  | WI025, WI  | PID-23      |
| • Multiple Birth Indicator   | Y (client was born as part of a multiple birth)                | PID-24      |
| • Birth Order  | 2 (second birth of a multiple birth)                           | PID-25      |
| • Publicity Code   | 02   | PD1-11      |
| • Protection Indicator   | Y (client records are visible by other provider organizations) | PD1-12      |
| • Patient Registry Status  | A (client is active in the registry)                           | PD1-14      |
| • Responsible Person (parent or other person who cares for client) |  | NK1 segment |
| • Name   | MARTHA MILLER  | NK1-2       |
| • Relationship to client   | MTH  | NK1-3       |
| • Address  | 123 MAIN ST<br>MADISON, WI 53000, W1025                        | NK1-4       |
| • Phone  | 608 123 4567   | NK1-5       |
| • Responsible Person   |  | NK1 segment |
| • Name   | GEORGE MILLER  | NK1-2       |
| • Relationship to client   | FTH  | NK1-3       |
| • Client #2  |  | PID segment |
| • Chart Number   | 23LK729  | PID-3       |
| • Name   | MARIA CALIFANO   | PID-5       |
| • Mother's maiden name   | ANGELICA DISTEFANO   | PID-6       |
| • Birth date   | April 13, 1998   | PID-7       |
| • Sex  | F  | PID-8       |
| • Immunization   |  | RXA segment |
| • Date administered  | July 23, 1999  | RXA-3       |
| • Vaccine  | DtaP   | RXA-5       |
| • CPT Code   | 90700  | RXA-5       |
| • Dose size  | 0.5  | RXA-6       |
| • Administering Provider Organization                              | Valley Clinic  | RXA-10      |
| • Immunization   |  | RXA segment |
| • Date administered  | July 23,1999   | RXA-3       |
| • Vaccine  | MMR  | RXA-5       |
| • CPT Code   | 90707  | RXA-5       |
| • Administering Provider Organization                              | Valley Clinic  | RXA-10      |

| Information to transmit               | Data value to be entered  | HL7 Format  |
|---------------------------------------|---|-------------|
| • Client #3                           |   | PID segment |
| • Chart Number                        | 92HG9257  | PID-3       |
| • Name                                | JOSEPH FISHER   | PID-5       |
| • Mother's maiden name                | MARY LASOWSKI   | PID-6       |
| • Birth date                          | May 28, 1998  | PID-7       |
| • Sex                                 | M   | PID-8       |
| • Immunization                        |   | RXA segment |
| • Date administered                   | July 29, 1999   | RXA-3       |
| • Vaccine                             | MMR   | RXA-5       |
| • CPT Code                            | 90707   | RXA-5       |
| • Dose                                | 0.5   | RXA-6       |
| • Administering Provider Organization | Valley Clinic   | RXA-10      |
| • Lot number                          | AD19487   | RXA-15      |
| • Lot expiration date                 | December 12, 1999   | RXA-16      |
| • Lot manufacturer                    | FLYBYNIGHT LABORATORIES (this manufacturer is not found in the valid list in HL7 Table 0227, and the invalid value will cause VIIS to reject the message with an error message) | RXA-17      |

In an HL7 message, each segment is a single text line, ending with the carriage return character. In the examples, long lines are broken artificially for display purposes and the carriage return character is denoted by <CR>.

```
FHS|^~\&|VALSYS|VALCLIN||VIIS|19990802091523||filename1.hl7|WEEKLY HL7
  UPLOAD|00009972<CR>
BHS|^~\&|VALSYS|VALCLIN||VIIS|19990802091523|||00010223<CR>
MSH|^~\&|VALSYS|VALCLIN||VIIS|19990802091524||ADT^A31|00000123|P|2.4|||AL<CR>
PID|||45LR999^^^^PI||MILLER^GEORGE^M^JR|OLSON^MARTHA|19950227|M|||123 MAIN
  ST^^MADISON^WI^53000^US^^^DANE|||||000111222|||US^WI^W1025|Y|2<CR>
PD1|||||||02^REMINDER/RECALL - ANY MENTOD^HL70215|Y|A<CR>
NK1|1|MILLER^MARTHA|MTH^Mother^HL70063|123 MAIN ST^^MADISON^WI^53000^US^^^W1025
  |(608)123-4567<CR>
NK1|2|MILLER^GEORGE|FTH^Father^HL70063<CR>
MSH|^~\&|VALSYS|VALCLIN||VIIS|19990802091524||VXU^04|00000124|P|2.4|||ER<CR>
PID|||66782^^^^SR^^23LK729^^^^PI|CALIFANO^MARIA|DISTEFANO^ANGELICA|19980413|F<CR>
RXA|0|999|19990723|19990723|^^^90700^DTaP^CPT|1.0|||VALCLIN<CR>
RXA|0|999|19990723|19990723|^^^90707^MMR^CPT|||VALCLIN<CR>
MSH|^~\&|VALSYS|VALCLIN||VIIS|19990802091526||VXU^04|00000125|P|2.4|||ER<CR>
PID|||927389^^^^SR^^92HG9257^^^^PI|FISHER^JOSEPH|LASOWSKI^MARY|19980528|M<CR>
RXA|0|999|19990729|19990729|^^^90707^MMR^CPT|1.0|||VALCLIN|||AD19487|
  19991212|ZZ^FLYBYNIGHT LABORATORIES^HL70227|||A<CR>
BTS|3<CR>
FTS|1<CR>
```

Note: When a client is being introduced to VIIS, the VXU message must precede the ADT message, since VIIS must have at least one immunization for a client before being added to the database. Sending ADT and VXU messages for the same client is redundant, since the VXU message is capable of reporting all information that is also found in the ADT.

In the example above, Valley Clinic sends a file of three HL7 messages to VIIS. Batch header/footer segments bracket the messages. The first message type is an ADT, which is used to send client demographic data without including immunization information. This message type MUST follow a VXU message for the client if the client is new to the VIIS system.

Client George M Miller Jr. is identified by Valley Clinic's chart number, 45LR999, in his PID segment. The message could have included George's VIIS ID number in field PID-3, but does not have to, if it is not recorded in Valley Clinic's system. George's mother's maiden name, birth date, sex, address, and social security number also serve to identify him. Some other optional fields are not present, including some fields from the full HL7 standard not defined in this document because they are not used by VIIS. Fields not present do not diminish the number of "I" delimiters, so later fields can be identified by ordinal

position in the segment. Two NK1 segments give some information for George's mother and father, just the minimum required for his father, with address and telephone fields for his mother.

The next two PID segments in the second and third messages give a VIIS client ID in field PID-3. This must have been transmitted earlier from VIIS to Valley Clinic's system. In this case it is legitimate to omit more of the optional PID fields, since VIIS must have at least the minimum required information for these clients even to create a record. However, if there is a possibility that Valley Clinic has new or changed information to send to VIIS, these fields should be present, and it does no harm to repeat fields even if they have been transmitted previously.

```
FHS|^~\&|VIIS|VIIS||VALCLIN|19990803200106||filename2.hl7||000023479|00009972<CR>
BHS|^~\&|VIIS|VIIS||VALCLIN|19990803200116|||00004321|00010223<CR>
MSH|^~\&|VIIS|VIIS||VALCLIN|19990803200117||ACK|00000456|P|2.4<CR>
MSA|AA|00000123<CR>
MSH|^~\&|VIIS|VIIS||VALCLIN|19990803200119||ACK|00000458|P|2.4<CR>
MSA|AE|00000125|INVALID MANUFACTURER CODE<CR>
ERR|RXA^152^17^1<CR>
BTS|2|<CR>
FTS|1<CR>
```

VIIS answers the file from the above example with a file of ACK messages. Valley Clinic's message 00000123 had the value AL in field MSH-15, asking for acknowledgements of all messages. The value AA in MSA-1 indicates that this message was processed without error. The next message, 00000124, uses the value ER to ask for acknowledgement only in case of errors, so this message is acknowledged implicitly by the absence of an ACK message for it. This example while legitimate is for purposes of illustration and most providers will probably prefer to follow the VIIS recommendation of error acknowledgements only. The last message, 00000125, did contain an error, and the ERR segment in its acknowledgement indicates the segment ID (RXA) of the segment, the line number (152) where it appears in the input file, the errant field (17) and the field component (1). The MSA segment contains the error message. Errors will be generated for missing required data, invalid data or any other deviance from the form and content of messages as specified in this document. If all three messages in the first file above had requested error acknowledgement only and none had any errors, then the answering file from VIIS would contain just the FSH, BHS, BTS, and FTS segments. All the messages would be implicitly acknowledged as successfully processed.

In the sample file exchange above, the outside system initiated the exchange with the file of ADT and VXU segments and VIIS responded with ACK segments. The format is identical when VIIS sends ADT and VXU segments out and the ACK responses are similar too. In the FHS, BHS, and MSH segments, the values of the fourth and sixth fields are reversed to show sender and receiver. VIIS always sends its own client identifier in the required field PID-03 and includes the outside system's identifier in PID-03 if known. Outside systems are encouraged to store VIIS's client ID, and use it in PID-03 when sending to VIIS. This provides a firm basis for client identification makes processing easier for the VIIS system and avoids errors in storing client information, such as creation of duplicate records when an insufficiently identified client record cannot be matched with a record already in the VIIS database. Though VIIS makes a great effort to match client records effectively, use of the VIIS client ID is the best guarantee of clean and useful data.

## Real-time Processing

“Real-time” processing refers to the ability to transmit an HL7 2.4 formatted VXQ^V01 Message (Query for Vaccination Record) and a VXU^V04 Message (Unsolicited Vaccination Update) and receive from VIIS the resulting HL7 2.4 Response Message in real time. A provider organization will query a registry to get information on a certain client (i.e. send an HL7 2.4 VXQ^V01 message) and will receive an HL7 2.4 Message Response (i.e. VXR^V03, VXX^V02, ACK or QAK) to that query in real time

In order to have this capability, provider organizations need to perform the following:

1. Obtain or develop, install and configure a client interface capable of transmitting an HL7 formatted Message file via the Electronic Business using eXtensible Markup Language (ebXML) infrastructure to securely transmit public health information over the Internet to the Public Health Information Network Messaging System (PHINMS) Message Receiver.  
The CDC provides, free of charge, their PHINMS client Message Sender for communication with their PHINMS Message Receiver. Alternatively, the provider may choose to develop their own ebXML Message Sender to communicate with the PHINMS Message Receiver.
2. The provider organization will submit a text file containing HL7 2.4 formatted VXQ^V01 and VXU^V04 Messages (up to 1000 messages are accepted) to be delivered via their ebXML-based client Message Sender to the VIIS PHINMS Message Receiver. VIIS will process the Messages and send back via the PHINMS Message Receiver a file of HL7 2.4 formatted Response Messages, one per associated query or vaccination update request.
3. It is the responsibility of the provider organization to obtain or develop, install and configure an ebXML client Message Sender for sending the HL7 2.4 formatted Message Requests and receiving the resulting HL7 2.4 formatted Message Response file generated by VIIS
4. The provider organization will need to obtain from VIIS a CPA (Collaboration Protocol Agreement) for access to the VIIS Real-time system.
5. The provider organization will need to obtain the VIIS SSL certificate for secure access. See Appendix C (Obtaining the VIIS SSL Certificate) for detailed instructions. Please note: your certificate must be renewed annually. You will need to repeat the procedure detailed in Appendix C on an annual basis.

**\*\*VIIS PROVIDES NEITHER INSTALLATION, CONFIGURATION NOR TECHNICAL SUPPORT FOR THE EBXML CLIENT MESSAGE SENDER.**

Full documentation and contact information for the PHINMS product may be found at the following link:

<http://www.cdc.gov/phinf/>

Full documentation for the ebXML specification may be found at the following link:

<http://www.ebxml.org/specs>

PHINMS is ebXML version 2.0 compliant.

The following section outlines the various message types that are sent in real-time files.

Real-time files that provider organizations send to the VIIS can contain any of the following message types:

### VXU^V04

Unsolicited Vaccination Update

|         |  |
|---------|--|
| MSH     | Message Header   |
| PID     | Patient Identification   |
| [PD1]   | Patient Additional Demographic   |
| [{NK1}] | Next of Kin / Associated Parties   |
| [PV1]   | Patient Visit  |
| RXA     | Pharmacy / Treatment Administration (at least ONE RXA is REQUIRED by VIIS) |
| [RXR]   | Pharmacy / Treatment Route (Only one RXR per RXA segment)                  |
| [{OBX}] | Observation/Result   |

### VXQ^V01

Query for Vaccination Record

|     |  |
|-----|--|
| MSH | Message Header Segment                                     |
| QRD | Query Definition Segment                                   |
| QRF | Query Filter Segment (VIIS has made this segment REQUIRED) |

Real-time (response) files that the VIIS sends to provider organizations can contain any of the following message types:

#### VXR^V03

Response TO Vaccination Query Returning the Vaccination Record

|         |  |
|---------|--|
| MSH     | Message Header Segment (One per message)                         |
| MSA     | Message Acknowledgment Segment (One per message)                 |
| QRD     | Query Definition Segment (One per message)                       |
| QRF     | Query Filter Segment (One per message—required by VIIS)          |
| PID     | Patient Identification Segment (One per matching client)         |
| [PD1]   | Additional Demographics  |
| [[NK1]] | Next of Kin Segment (Optional, zero or more per matching client) |
| [PV1]   |  |
| [[      |  |
| RXA     | Pharmacy Administration  |
| [RXR]   | Pharmacy Route   |
| [[OBX]] | Observation/Result Contraindications or Reactions                |
| ]]      |  |
| [[OBX]] | Observation/Result Vaccines Due Next                             |

#### VXX^V03

Response TO Vaccination Query (Returning Multiple PID Matches)

|         |  |
|---------|--|
| MSH     | Message Header Segment (One per message)                         |
| MSA     | Message Acknowledgment Segment (One per message)                 |
| QRD     | Query Definition Segment (One per message)                       |
| QRF     | Query Filter Segment (One per message—required by VIIS)          |
| {       |  |
| PID     | Patient Identification Segment (One per matching client)         |
| [[NK1]] | Next of Kin Segment (Optional, zero or more per matching client) |
| }       |  |

#### ACK

General Acknowledgment

|       |                                |
|-------|--------------------------------|
| MSH   | Message Header Segment         |
| MSA   | Message Acknowledgment Segment |
| [ERR] | Error                          |

#### QCK

Query General Acknowledgment

|       |                                |
|-------|--------------------------------|
| MSH   | Message Header Segment         |
| MSA   | Message Acknowledgment Segment |
| [ERR] | Error                          |
| [QAK] | Query Acknowledgment Segment   |

Page 6 of this document outlines the rules/specifications needed to construct a HL7 message. These same rules must be applied for Real-time message processing. **\*\*Note:** Batch Message Headers (i.e. FHS, BHS) and footers (i.e. FTS, BTS) are NOT required for Real-time processing.

The message segments below are needed to construct message types that are used by VIIS. Each segment is given a brief description excerpted from the HL7 standard. The tables define what fields make up each segment. Since VIIS does not use all the fields that HL7 defines, there are sometimes gaps in the ordinal sequence of fields. Following HL7 rules, the gaps do not diminish the number of field separators within the segment. For example, if the second and third fields in a segment are not present, their field separators remain in order to indicate that the next field present is the fourth: field1|||field4.

#### MSH

Message Header Segment

For VXU and VXQ message types, the MSH segment must be constructed according to normal HL7 format specifications (refer to Pg. 5 of this document). For Real-time processing, VIIS limits the number of MSH segments that can be processed in a single file. Files containing more than 1000 MSH segments will be rejected and an ACK message will be generated, informing the provider that 1000 is the maximum number of MSH segments that VIIS accepts for Real-time processing.

**VXU^V04****Unsolicited Vaccination Record Update**

As stated earlier in this document, the VXU message is used for sending client demographic and immunization specific data. This message type can be sent via Real-time. VXU segments should be constructed according to normal HL7 format specifications (refer to pages 5-9 of this document). A VXU message must be received in the HL7 2.4 format; VIIS does not support prior HL7 versions for Real-time processing. VIIS validates the version by reading the MSH-12 field. A VXU message must contain |2.4^^| in MSH-12.

Immunization deletions can be submitted for both batch HL7 2.4 and Real-time submissions. To indicate a deletion, the RXA-21 field must be populated with a value of “D”. Below is an example of a RXA deletion segment. If the number of deletions received through batch exceeds 5% of the total number of immunizations or more than 50 immunizations are marked for deletion, VIIS will reject the file.

RXA|0|999|19860715|19860715|^^^90718^Td^CPT|0|||05^^^^|||^^208^^^^^^^^^^^^^^^^|||D|

**VXQ^V01****Query for Vaccination Record**

When a health care provider (participating in an immunization registry) needs to obtain a complete patient vaccination record, a VXQ (query) is sent to the immunization registry for the definitive (last updated) immunization record. The three segments that make up a VXQ message are the MSH (message header), QRD (query definition) and QRF (query filter). For a VXQ message, the MSH-09 field must contain |VXQ^V01| and the segments must be in the following sequence order:

**MSH|^~\&|VIISPH|VIISPH|VIISPH|VIISPH|200212091511||VXQ^V01|00000001P^|2.4|||ER**

**QRD||9970522IR|||000000001|||25^RD|01^KENNEDY^JOHN^FITZGERALD^JR|VXII^VACCINE INFORMATION^HL700048|^S11SI**

**QRF|MA0000|||256946789~19900607~MA~MA99999999~88888888~KENNEDY^JACQUELINE^LEE~BOUVIER~898666725~KENNEDY^JOHN^FITZGERALD~822546618|**

The QRD and QRF segments are outlined in detail below.

**QRD****Query Definition Segment**

Used to define a query.

| SEQ | LEN | DT  | R/O | RP/# | TBL# | ELEMENT NAME                   |
|-----|-----|-----|-----|------|------|--------------------------------|
| 1   | 26  | TS  | R   |      |      | Query date/time                |
| 2   | 1   | ID  | R   |      | 0106 | Query Format Code              |
| 3   | 1   | ID  | R   |      | 0091 | Query Priority                 |
| 4   | 10  | ST  | R   |      |      | Query ID                       |
| 5   | 1   | ID  | O   |      | 0107 | Deferred response type         |
| 6   | 26  | TS  | O   |      |      | Deferred response date/time    |
| 7   | 10  | CQ  | R   |      | 0126 | Quantity limited request       |
| 8   | 60  | XCN | R   | Y    |      | Who subject filter             |
| 9   | 60  | CE  | R   | Y    | 0048 | What subject filter            |
| 10  | 60  | CE  | R   | Y    |      | What department data code      |
| 11  | 20  | CM  | O   | Y    |      | What data code value qualifier |
| 12  | 1   | ID  | O   |      | 0108 | Query results level            |

***Field Notes:***

- QRD-01 Date the query was generated by the application program. VIIS requires this field and verifies that a valid date is received. The minimum format of YYYYMMDD is required. A null/invalid value results in message rejection.
- QRD-02 Query/response format code. VIIS requires this field and only accepts a value of “R”. A null/invalid value results in message rejection.
- QRD-03 Time frame in which the response is expected. VIIS requires this field and only accepts a value of “T”. A null/invalid value results in message rejection.
- QRD-04 Unique identifier for the query assigned by the querying application. VIIS requires this field and null/invalid values result in message rejection. This field is returned intact by VIIS in a response (VXR or VXX).
- QRD-05 Used to indicate a deferred response. This is an optional field. VIIS does not support a deferred response.
- QRD-06 Used to indicate the date/time of the deferred response. This is an optional field. VIIS does not support a deferred response.

QRD-07 Maximum length of the response that can be accepted by the requesting system. VIIS requires this field and only accepts a value of “RD” in the 2nd component. The 1st component is a numerical value. A null/invalid value in either sub-component results in message rejection. VIIS will interpret the units as the maximum number of client MATCHES to be returned via a VXX response message.

\*Note: VIIS will return a maximum of 10 records per query message submitted. If a value of 0 (zero) is received (i.e. 0^RD) then VIIS will return the maximum allowable number of clients found to be matching the VIIS.

QRD-08 Identifies the subject of the query or whom the inquiry is about. The 2<sup>nd</sup> component is required by VIIS. If the first or last name OR both names are missing (regardless if there are repeating full names after the first) it results in message rejection. VIIS supports repetition of this field.

QRD-09 Describes the kind of information required to satisfy the request. VIIS requires this field and a value of “VXI” must populate the 1<sup>st</sup> component. VIIS supports repetition of this field. Null/invalid values result in message rejection if the field does not repeat. If the field repeats there must be at least one value of “VXI” to be valid.

QRD-10 Identifies the “what” department data code. VIIS requires this field and supports repetition of it. Null/invalid values will result in message rejection.

QRD-11 Further refines the inquiry by data code qualifiers by providing a window or range. This is an optional and repeatable field.

QRD-12 Used to control level of detail in results. This field is optional and will be populated by VIIS with the total count of PID matches found in VIIS when Query results in a VXX Response Message.

**Example:**

QRD|19970522|R||000000001||25^RD|01^KENNEDY^JOHN^FITZGERALD^JR|VX|^VACCINE INFORMATION^HL700048|^S11S|20

**QRF – Query Filter Segment – REQUIRED by VIIS**

Used with the QRD segment to further refine the content of a query.

| SEQ | LEN | DT | R/O | RP/# | TBL# | ELEMENT NAME                     |
|-----|-----|----|-----|------|------|----------------------------------|
| 1   | 20  | ST | R   | Y    |      | Where subject filter             |
| 2   | 26  | TS | O   |      |      | When data start date/time        |
| 3   | 26  | TS | O   |      |      | When data end date/time          |
| 4   | 60  | ST | O   | Y    |      | What user qualifier              |
| 5   | 60  | ST | O   | Y    |      | Other query subject filter       |
| 6   | 12  | ID | O   | Y    | 0156 | Which data/time qualifier        |
| 7   | 12  | ID | O   | Y    | 0157 | Which date/time status qualifier |
| 8   | 12  | ID | O   | Y    | 0158 | Date/time selection qualifier    |
| 9   | 60  | TQ | O   | Y    |      | When quantity/timing qualifier   |

**Field Notes:**

QRF-01 Identifies the department, system or subsystem to which the query pertains. VIIS requires this field. A null/invalid value results in message rejection.

QRF-02 Data representing dates and times (registries do not value this component). This is an optional field.

QRF-03 Data representing dates and times (registries do not value this component). This is an optional field.

QRF-04 An identifier to further define characteristics of the data of interest. This is an optional field.

QRF-05 This field is used by registries to transmit up to ten separate search “keys”. VIIS requires this field and does NOT support repetition. The 2<sup>nd</sup> component (patient DOB) is minimally required by VIIS. A null/invalid format results in message rejection. Format is YYYYMMDD.

**Example:**

QRF|MA0000|||256946789~19900607~MA~MA99999999~88888888~KENNEDY^JACQUELINE^LEE~BOUVIER~898666725~KENNEDY^JOHN^FITZGERALD~822546618|

**VXR^V03 – Response TO Vaccination Query (Returning the Vaccination Record)**

When a patient has been uniquely identified (there is only one “match” to the query), the response to the query is a VXR^V03 message that is generated and sent back to the querying organization. VIIS has imposed rules for when a VXR will be sent to the querying organization. Please see the following rules:

1. If an exact match is found in VIIS AND the client’s “Allow Sharing of Immunization Data” indicator is set to “NO”, then that client will **NOT** be returned to the requestor unless one of the statements below pertains:
  - The organization requesting the query is the Master organization of a Parent organization owning the data **OR**
  - The organization requesting the query had originally set the “Allow Sharing of Immunization Data” indicator to NO.
2. If an exact match is found in VIIS AND the client’s “Allow Sharing of Immunization Data” indicator is set to “NO” (and none of the above rules apply), then a QCK response is sent instead of the VXR message.
3. VIIS will only return eligible vaccines. VIIS will not supply vaccines that are ineligible due to age restrictions, contraindications or other such rules. VIIS will supply vaccines according to CDC/ACIP schedule.

**VXR segment detail**

Several segments make up the VXR message type. The following segments have been outlined previously in this document and will follow the same formatting for the VXR message type.

MSH, MSA, QRD, QRF, PID, PD1, NK1, PV1, RXA, RXR, OBX (Observation/Result Contraindications or Reactions)

In addition to supplying the querying organization with client specific demographic and immunization data (contained in the above segments), the VXR message also specifies “Observation/Result Vaccines Due Next” information. This information is supplied by generating a minimum of 3 OBX segments per 1 recommendation. VIIS will report the Vaccination Schedule in the OBX segments through the specification of the LOINC code 30979-9 (Vaccines Due Next) and its sub-components in OBX-03. VIIS requires specification of OBX-05 when OBX-03 is specified and valid. Further, VIIS has superimposed a CE data type on the OBX-05 field. The corresponding observation values will be specified in OBX-05. Combinations are as follows:

**OBX-03**

30979-9

30979-9&30980-7

30979-9&30981-5

**OBX-05**

HL70292 (Codes for vaccines administered CVX)

Date Vaccine Due (VIIS provides date recommended)

Earliest date to give (VIIS provides)

Below you’ll find an example of what a recommendation might look like in a VXR message response (see **bolded** OBX’s below).

```
MSH|^~\&|VIIS|QUERYING ORG|20040101101||VXR^V04|001|P^|2.4|||IER
MSA|AA|001|
QRD|20040120|R||001||1^RD|01^LAST NAME^FIRST^MIDDLE^JR|VX|VACCINE INFORMATION^HL700048|S11S||1
QRF|MA000||~19900607~WI~STATEBIR#~MA#~KENNEDY^JACQUELINE^LEE~BOUVIER~898666725~KENNEDY^JOHN^FITZ
GERALD~822546618~587421369~19630119~MN~MN99999999~88888888~DOE^JANE^ROSE~SMITH~999999999~SMITH^JOHN^I~
999999999|
PID||1912484^~~~~|123^~PI^|Trolly 1A^Eliot^J^Sr^~|~~~~|19090509|M||~~~~|12017 N ROCK INN
RD^^AUBURNDALE^WI^54412^USA^~|(715)384-8649^~~~~~|~~~~~|A^|~~~~|
PD1|~~~~~|01^~~~~|Y|||A||
NK1||Hamus^Eugene^J^Sr^|SEL^SELF^HL70063|12017 N ROCK INN RD^^AUBURNDALE^WI^54412^USA^~|(715)384-
8649^~~~~~|
PV1|~~~~~|V00^20031208|
RXA|0|999|20021001|20021001|^~90721^Diphtheria, Tetanus, Acellular Pertussis + HIB^CPT|0||^Health Assessment & Promotion
(HAP)^Y|~~~~~|^HL70227|200210141430
RXR|M^~~~~|LA^~~~~
OBX|1|CE|30979-9^Vaccine due next^LN||20^DTAP^CVX^~|
OBX|2|TS|30979-9&30980-7^Date vaccine due^LN||20040130^~~~~|
OBX|3|NM|30979-9&30981-5^Earliest date to give^LN||20040111^~~~~|
```

**VXX^V03**

Response TO Vaccination Query (Returning Multiple PID Matches)

When a health care provider participating in an immunization registry needs to obtain a complete patient vaccination record, a query (VXQ message) is sent to the immunization registry for the definitive (last updated) immunization record. When a query results in multiple patient matches, the VXX message response is generated. The VXX contains multiple clients and their demographic information but does not contain their vaccination information. The number of matches that VIIS generates will



depend on what is specified in the first component of the incoming VXQ (QRD-07 Quantity Limited request field). VIIS will interpret the quantity specified in this field as the maximum number of client matches that the requester desires.

For example:

If the query results in 100 matches and the original quantity specified in QRD-07 was 10, then VIIS generates 10 PID (and if applicable, associated NK1) segments in the VXX response message.

VIIS has imposed rules for when a VXX will be sent to the querying organization. Please see the following rules:

1. If the “Allow Sharing of Immunization Data” indicator is set to No (in VIIS) for a client found matching the query, then that client will **NOT** be returned to the requestor unless one of the statements below pertains:
  - The requestor is the Master organization of the Parent organization owning the data OR
  - The organization requesting the query had originally set the “Allow Sharing of Immunization Data” to No.

The following scenarios outline when a VXX message will be sent back when multiple matches are found, but some of the matches have an “Allow Sharing of Immunization Data” indicator of “No”.

### Scenario 1:

The following paragraph holds true, assuming that the VXQ has 0 in QRD-07 (meaning that the provider org. wants the maximum number of clients sent back).

If VIIS matches 10 clients and only 2 of those clients have the “Allow Sharing of Immunization Data” indicator set to “Yes”, then those 2 clients will be sent back in the VXX message and the remaining 8 clients (having indicators of “No”) will not be sent back. The QRD-12 field (in the VXX) will reflect the total number of matches found in VIIS (10 in our example) and the querying organization will need to assume that the 8 clients that were not returned had the “Allow Sharing of Immunization Data” indicator set to “No”.

Example:

#### VXQ

```
MSH|^~\&||ZZ000||QUERYING ORG|20040101101101||VXQ^V01|001|P^2.4|||ER
QRD|20040120|R||01||0^RD|01^SALAMI^STUART^S^^|VXI^VACCINE INFORMATION^HL700048|^S11S||0
QRF|ZZ000||~19900607~|
```

#### VXX

```
MSH|^~\&||ZZ000||QUERYING ORG|20040101101101||VXX^V02|001|P^2.4|||ER
MSA|AA|001||0||0^Message Accepted^HL70357^^^
QRD|20040120|R||01||0^RD|01^SALAMI^STUART^S^^|VXI^VACCINE INFORMATION^HL700048|^S11S||10|
QRF|ZZ000||~19900607~|
PID||123^SR~^PI^SALAMI^BRAD^S^|19900607|M||^
PID||456^SR~^PI^SALAMI^CHARLES^|19900706|M||^
NK1||SALAMI^CHARLES^SEL^SELF^HL70063|123 STREET ADDRESS^CITY^WI^55555^USA^^(608)555-6666^
```

### Scenario 2:

If VIIS matches 2 clients and both have the “Allow Sharing of Immunization Data” indicator set to “No”, then a QCK is generated. The QCK message will be comprised of the MSH, MSA and QAK segments. The MSA-01 field will have a value of “AR” (Application Reject). The MSA-03 field will display a message similar to “Client has an Allow Sharing of Immunization Data indicator = No”. MSA-06 text will display, "Record not released".

Example:

#### VXQ

```
MSH|^~\&||ZZ000||QUERYING ORG|20040101101101||VXQ^V01|007|P^2.4|||ER
QRD|20040120|R||01||0^RD|01^TEST INDICATOR^NO^|VXI^VACCINE INFORMATION^HL700048|^S11S||
```

#### QCK

```
MSH|^~\&||ZZ000||QUERYING ORG|20040101101101||VXX^V02|007|P^2.4|||ER
MSA|AR|007|Client has an Allow sharing of immunization data indicator = No||500^Record Not Released^HL70357^^^
QAK|01|NFI
```

### ACK

Acknowledgment Messages (with Errors)

ACK messages are generated for message rejections and for informational error messages. Three conditions that result in message rejection are:

1. Sequencing (i.e. a PID segment must follow an MSH segment.

2. Segment required fields contain no data.
3. Segment required fields contain invalid data.

An ACK is also generated when an informational error message has occurred, but it has not resulted in message rejection (i.e. NK1 segment contains no last name). In this case, the segment is ignored but the remainder of the message is processed. An ACK message is generated with a message informing the sender of the problem. The error message in the text does NOT include "Message Rejected". The ACK contains the MSH, MSA and ERR segments.

The MSH segment is generated according to normal HL7 processing guidelines. The MSA and ERR segments are detailed below:

### MSA

#### Message Acknowledgment Segment

| SEQ | LEN | DT | R/O | RP/# | TBL# | ELEMENT NAME                |
|-----|-----|----|-----|------|------|-----------------------------|
| 1   | 2   | ID | R   |      | 0008 | Acknowledgment code         |
| 2   | 20  | ST | R   |      |      | Message control ID          |
| 3   | 80  | ST | O   |      |      | Text message                |
| 4   | 15  | NM | O   |      |      | Expected sequence number    |
| 5   | 1   | ID | B   |      | 0102 | Delayed acknowledgment type |
| 9   | 100 | CE | O   |      |      | Error condition             |

#### Field Notes:

MSA-01 The acknowledgment code indicates whether the message was accepted, rejected, error, etc... This is a required field. VIIS generates an "AE" for messages resulting in informational or rejection errors. An "AA" is generated for a simple acknowledgment acceptance.

MSA-02 The message control ID is the unique ID that is sent by the sending system. This is a required field. It allows the sending system to associate each message with a response. In a response, this will be the same as the control ID that was sent in MSH-10 by the sending system.

MSA-03 This optional field further describes an error condition. When a message has been rejected, VIIS generates "Message Rejection" as the first portion of the text describing the error message. Informational messages will not contain "Message Rejection".

MSA-04 This optional numeric field is used in the sequence number protocol. VIIS does not generate this field.

MSA-05 Delayed Acknowledgement type. VIIS does not generate this field.

MSA-06 Error Condition. VIIS does not generate this field.

### ERR

#### Error Segment

The Error segment (ERR) is used to add error comments to acknowledgment messages. If the message was rejected for functional reasons, this segment will locate the error and describe it using locally established codes. Field components include:  
**<segment ID (ST)>^<sequence (NM)>^<field position (NM)>^<code identifying error (CE)>**

| SEQ | LEN | DT | R/O | RP/# | TBL# | ELEMENT NAME            |
|-----|-----|----|-----|------|------|-------------------------|
| 1   | 80  | CM | R   |      | 0357 | Error code and location |

#### Example:

#### ACK

MSH|^~\&||ZZ000||QUERYING ORG|20040101101||VXQ^V01|001|P^|2.4|||ER

MSA|AE|001||Invalid relationship code. Defaulting to Guardian|3||102^Invalid data value^HL70357^^^

ERR|NK1^16^3^0

### QCK

#### Query General Acknowledgment

A QCK message is generated when VIIS has processed the query message, but no match was found to the query parameters in the database. VIIS does NOT generate this response message for anything other than no match found (for successful VXQ processing). Remember, error messages are reported through the use of the ACK response message; therefore, the optional [ERR] segment will never be generated for the QCK response message.

The MSH segment is generated according to normal HL7 processing guidelines. The MSA and QAK segments are detailed below:

### MSA

#### Message Acknowledgment Segment

| SEQ | LEN | DT | R/O | RP/# | TBL# | ELEMENT NAME                |
|-----|-----|----|-----|------|------|-----------------------------|
| 1   | 2   | ID | R   |      | 0008 | Acknowledgment code         |
| 2   | 20  | ST | R   |      |      | Message control ID          |
| 3   | 80  | ST | O   |      |      | Text message                |
| 4   | 15  | NM | O   |      |      | Expected sequence number    |
| 5   | 1   | ID | B   |      | 0102 | Delayed acknowledgment type |
| 9   | 100 | CE | O   |      |      | Error condition             |

#### Field Notes:

MSA-01 The acknowledgment code indicates whether the message was accepted, rejected, error, etc...This is a required field. VIIS generates an AA for this field if no match is found in VIIS. An AR is generated if a match is found, but the "Allow sharing of data" indicator is No.

MSA-02 The message control ID is the unique ID that is sent by the sending system. This is a required field. It allows the sending system to associate each message with a response. In a response, this will be the same as the control ID that was sent in MSH-10 by the sending system.

MSA-03 This optional field further describes an error condition. When a message has been rejected, VIIS generates "Message Rejection" as the first portion of the text describing the error message. Informational messages will not contain "Message Rejection".

MSA-04 This optional numeric field is used in the sequence number protocol. VIIS does not generate this field.

MSA-05 Delayed Acknowledgement type. VIIS does not generate this field.

MSA-06 Error Condition. Refer to HL7 table 0357 for possible values.

### QAK

#### Query Acknowledgment Segment

| SEQ | LEN | DT | R/O | RP/# | TBL#  | ELEMENT NAME          |
|-----|-----|----|-----|------|-------|-----------------------|
| 1   | 32  | ST |     |      | 00696 | Query Tag             |
| 2   | 2   | ID | O   |      | 00708 | Query response status |

#### Field Notes:

QAK-01 This field is valued by the initiating system to identify the query and can be used to match response messages to the originating query. If it is valued, the responding system is required to echo it back as the first field in the QAK. VIIS uses the value specified in the QRD-04 (of the VXQ) for the QAK-01 query tag value.

QAK-02 This field allows the responding system to return a precise response status. Refer to HL7 table 0208 for values. VIIS only generates NF (no data found, no errors) for this field.

Example:

#### QCK

MSH|^~\&||ZZ000||QUERYING ORG|20040101101||VXX^V02|007|P^|2.4|||ER

MSA|AR|007|Client has an Allow sharing of immunization data indicator = No||500^Record Not Released^HL70357^^|

QAK|01|NF|

This concludes real-time processing.

## Appendix A -- HL7 Data Types

The following descriptions of HL7 data types are excerpted or adapted from the HL7 standard. See the field notes within each segment definition above on how to use data types in particular fields. Some data types have complex definitions much of which do not apply to VIIS usage, and for these we omit much of the HL7 definition of the data type, referring instead to the field notes in the segment definitions.

### CE

#### Coded Element

Components: <identifier (ST)> ^ <text (ST)> ^ <name of coding system (ST)> ^ <alternate identifier (ST)> ^ <alternate text (ST)> ^ <name of alternate coding system (ST)>

Example:

```
|F-11380^CREATININE^I9^2148-5^CREATININE^LN|
```

This data type transmits codes and the text associated with the code. To allow all six components of a CE data type to be valued, the maximum length of this data type must be at least 60.

#### Identifier (ST)

Sequence of characters (the code) that uniquely identifies the item being referenced by the <text>. Different coding schemes will have different elements here.

#### Text (ST)

Name or description of the item in question. E.g., myocardial infarction or X-ray impression. Its data type is string (ST).

#### Name of coding system (ST)

Each coding system is assigned a unique identifier. This component will serve to identify the coding scheme being used in the identifier component. The combination of the **identifier** and **name of coding system** components will be a unique code for a data item. Each system has a unique identifier. ASTM E1238-94, Diagnostic, procedure, observation, drug ID, and health outcomes coding systems are identified in the tables in Section 7.1.4 [of the full HL7 standard], "Coding schemes." Others may be added as needed. When an HL7 table is used for a CE data type, the **name of coding system** component is defined as **HL7nnnn** where **nnnn** is the HL7 table number.

#### Alternate components

These three components are defined analogously to the above for the alternate or local coding system. If the Alternate Text component is absent, and the Alternate Identifier is present, the Alternate Text will be taken to be the same as the Text component. If the Alternate Coding System component is absent, it will be taken to mean the locally defined system.

**Note:** The presence of two sets of equivalent codes in this data type is semantically different from a repetition of a CE-type field. With repetition, several distinct codes (with distinct meanings) may be transmitted.

**Note:** For HL7-defined tables which have not been adopted from some existing standard, the third component, "name of coding system," is constructed by appending the table number to the string "HL7." Thus, the field *RXR-2-site*, is a CE data type which refers to HL7 table number 0163. Its "name of coding system" component is "HL70163".

### CM

#### Composite

Components: <point of care (IS)> ^ <room (IS) ^ <bed (IS)> ^ <facility (HD) ^ <location status (IS) ^ <patient location type (IS)> ^ <building (IS)> ^ <floor (IS)> ^ < street address (ST)> ^ <other designation (ST)> ^ <city (ST)> ^ <state or province (ST)> ^ <zip or postal code (ST)> ^ <country (ID)> ^ <address type (ID)> ^ <other geographic designation (ST)>

Subcomponents of facility (HD): <namespace ID (IS)> & <universal ID (ST)> & <universal ID type (ID)>

Example:

```
|^^^Valley Clinic|
```

Definition: The first component contains the inpatient or outpatient location at which the drug or treatment was administered (if applicable). The default (null) value is the current census location for the patient. Site-specific table. The first eight components have the same form as the first eight components of *PVI-3-assigned patient location*. The final eight components replace the ninth component of *PVI-3-assigned patient location* and represent the full address specification.

### CX

#### Extended Composite ID with Check Digit

VIIS uses this data type only for client identification in Patient Identification (PID) segments. See the field notes for values used for VIIS.

### HD

Hierarchic Designator

VIIS uses this data type only to identify sender and receiver in Message Header (MSH) segments. See the field notes for values used for VIIS.

### ID

Coded Value for HL7 Defined Tables

The value of such a field follows the formatting rules for a ST field except that it is drawn from a table of legal values. There shall be an HL7 table number associated with ID data types. Examples of ID fields include religion and sex. This data type should be used only for HL7 tables. The reverse is not true, since in some circumstances it is more appropriate to use the CE data type for HL7 tables.

### IS

Coded Value for User Defined Tables

The value of such a field follows the formatting rules for a ST field except that it is drawn from a site-defined (or user-defined) table of legal values. There shall be an HL7 table number associated with IS data types. An example of an IS field is the *Event reason code* defined in Section 3.3.1.4 [of the full HL7 standard], "Event reason code." This data type should be used only for user-defined tables. The reverse is not true, since in some circumstances, it is more appropriate to use the CE data type for user-defined tables.

### NM

Numeric

A number represented as a series of ASCII numeric characters consisting of an optional leading sign ( + or -), the digits and an optional decimal point. In the absence of a sign, the number is assumed to be positive. If there is no decimal point the number is assumed to be an integer. Examples:

| 999 |

| -123.792 |

Leading zeros, or trailing zeros after a decimal point, are not significant. For example, the following two values with different representations, "01.20" and "1.2", are identical. Except for the optional leading sign ( + or -) and the optional decimal point (.), no non-numeric ASCII characters are allowed. Thus, the value <12 should be encoded as a structured numeric (SN) (preferred) or as a string (ST) (allowed, but not preferred) data type.

### SI

Sequence ID

A non-negative integer in the form of a NM field. See the field notes in segments using this data type for specifications of SI fields.

### ST

String Data

String data is left justified with trailing blanks optional. Any displayable (printable) ACSII characters (hexadecimal values between 20 and 7E, inclusive, or ASCII decimal values between 32 and 126), except the defined delimiter characters.

Example:

|almost any data at all|

To include any HL7 delimiter character (except the segment terminator) within a string data field, use the appropriate HL7 escape sequence.

Usage note: the ST data type is intended for short strings (e.g., less than 200 characters). For longer strings the TX or FT data types should be used.

### TS

Time Stamp

Format: YYYY[MM[DD[HHMM[SS[.S[S[S[S]]]]]]][+/-ZZZZ]^<degree of precision>

Contains the exact time of an event, including the date and time. The date portion of a time stamp follows the rules of a date field and the time portion follows the rules of a time field. The specific data representations used in the HL7 encoding rules are compatible with ISO 8824-1987(E).

**In prior versions of HL7, an optional second component indicates the degree of precision of the time stamp (Y = year, L = month, D = day, H = hour, M = minute, S = second). This optional second component is retained only for purposes of backward compatibility.**

By site-specific agreement, YYYYMMDD[HHMM[SS[S[S[S[S]]]]][+/-ZZZZ]^<degree of precision> may be used where backward compatibility must be maintained.

In the current and future versions of HL7, the precision is indicated by limiting the number of digits used, unless the optional second component is present. Thus, YYYY is used to specify a precision of “year,” YYYYMM specifies a precision of “month,” YYYYMMDD specifies a precision of “day,” YYYYMMDDHH is used to specify a precision of “hour,” YYYYMMDDHHMM is used to specify a precision of “minute,” YYYYMMDDHHMMSS is used to specify a precision of seconds, and YYYYMMDDHHMMSS.SSSS is used to specify a precision of ten thousandths of a second. In each of these cases, the time zone is an optional component. Maximum length of the time stamp is 26. Examples:

```
|19760704010159-0600| 1:01:59 on July 4, 1976 in the Eastern
                        Standard Time zone.
|19760704010159-0500| 1:01:59 on July 4, 1976 in the Eastern
                        Daylight Saving Time zone.
|198807050000|       Midnight of the night extending from July 4 to
                        July 5, 1988 in the local time zone of the sender.
|19880705|           Same as prior example, but precision extends
                        only to the day. Could be used for a
                        birthdate, if the time of birth is unknown.
```

The HL7 Standard strongly recommends that all systems routinely send the time zone offset but does not require it. All HL7 systems are required to accept the time zone offset, but its implementation is application specific. For many applications the time of interest is the local time of the sender. For example, an application in the Eastern Standard Time zone receiving notification of an admission that takes place at 11:00 PM in San Francisco on December 11 would prefer to treat the admission as having occurred on December 11 rather than advancing the date to December 12.

One exception to this rule would be a clinical system that processed patient data collected in a clinic and a nearby hospital that happens to be in a different time zone. Such applications may choose to convert the data to a common representation. Similar concerns apply to the transitions to and from daylight saving time. HL7 supports such requirements by requiring that the time zone information be present when the information is sent. It does not, however, specify which of the treatments discussed here will be applied by the receiving system.

## XAD

### Address

Components: <street address (ST)> ^ <other designation (ST)> ^ <city (ST)> ^ <state or province (ST)> ^ <zip or postal code(ST)> ^ <country (ID)> ^ < address type (ID)> ^ <other geographic designation (ST)>^ <county/parish code (IS)> ^ <census tract (IS)> ^ <address representation code (ID)>

### Example:

```
|1234 Easy St.^Ste. 123^San Francisco^CA^95123^USA^B^^SF^^|
```

## Street address (ST)

The street or mailing address of a person or institution.

## Other designation (ST)

Second line of address. In general, it qualifies address. Examples: Suite 555 or Fourth Floor.

## City (ST)

## State or province (ST)

State or province should be represented by the official postal service codes for that country.

## Zip or postal code (ST)

Zip or postal codes should be represented by the official codes for that country. In the US, the zip code takes the form 99999[-9999], while the Canadian postal code takes the form A9A-9A9.

## Country (ID)

Defines the country of the address. See Table 0212.

## Address type (ID)

Address type is optional.

## Other geographic designation (ST)

Other geographic designation includes country, bioregion, SMSA, etc.

### **County/parish code (IS)**

A code that represents the county in which the specified address resides. Refer to *user-defined table 0289 - County/parish*. When this component is used to represent the county (or parish), component 8 “other geographic designation” should not duplicate it (i.e., the use of “other geographic designation” to represent the county is allowed only for the purpose of backward compatibility, and should be discouraged in this and future versions of HL7).

### **Census tract (IS)**

An optional code that represents the census track in which the specified address resides. VIIS does not store this value.

### **XCN**

Extended Composite ID Number and Name for Persons

VIIS uses this data type only to identify Provider Organizations that administer immunizations. See the field notes for segment RXA.

### **XPN**

Extended Person Name

Components: <family name (ST)> & <last name prefix (ST)> ^ <given name (ST)> ^ <middle initial or name (ST)> ^ <suffix (e.g., JR or III) (ST)> ^ <prefix (e.g., DR) (ST)> ^ <degree (e.g., MD) (ST)> ^ <name type code (ID)> ^ <name representation code (ID)>

Example:

|Smith&St^John^J^III^DR^PHD^L|

Family name (ST)

Last Name Prefix (ST)

Given name (ST)

Middle initial or name (ST)

### **Suffix (ST)**

Used to specify a name suffix (e.g., Jr. or III).

### **Prefix (ST)**

Used to specify a name prefix (e.g., Dr.).

### **Degree (ST)**

Used to specify an educational degree (e.g., MD).

### **Name type code (ID)**

A code that represents the type of name. Refer to *HL7 table 0200 - Name type* for valid values.

Table 0200 - Name type

| Value | Description  |
|-------|--------------|
| A     | Alias Name   |
| L     | Legal Name   |
| D     | Display Name |
| M     | Maiden Name  |
| C     | Adopted Name |

Note: The legal name is the same as the current married name.

### **Name representation code (ID)**

This component can be used when names are represented in ideographic or non-alphabetic systems. VIIS ignores this component.

### **XTN**

Extended Telecommunication Number

Components: [NNN] [(999)]999-9999 [X999999] [B999999] [C any text] ^ <telecommunication use code (ID)> ^ <telecommunication equipment type (ID)> ^ <email address (ST)> ^ <country code (NM)> ^ <area/city code (NM)> ^ <phone number (NM)> ^ <extension (NM)> ^ <any text (ST)>

Example:

(415) 555-3210^ORN^FX^

**[(999)] 999-9999 [X99999] [C any text]**

Defined as the TN data type, except that the length of the country access code has been increased to three.

### **Telecommunication use code (ID)**

A code that represents a specific use of a telecommunication number. Refer to *HL7 table 0201 - Telecommunication use code* for valid values.

Table 0201 - Telecommunication use code

| Value | Description              |
|-------|--------------------------|
| PRN   | Primary Residence Number |
| ORN   | Other Residence Number   |
| WPN   | Work Number              |
| VHN   | Vacation Home Number     |
| ASN   | Answering Service Number |
| EMR   | Emergency Number         |
| NET   | Network (email) Address  |
| BPN   | Beeper Number            |

### **Telecommunication equipment type (ID)**

A code that represents the type of telecommunication equipment. Refer to *HL7 table 0202 - Telecommunication equipment type* for valid values. Table 0202 - Telecommunication equipment type

| Value    | Description  |
|----------|--|
| PH       | Telephone  |
| FX       | Fax  |
| MD       | Modem  |
| CP       | Cellular Phone   |
| BP       | Beeper   |
| Internet | Internet Address: Use Only If Telecommunication Use Code Is NET    |
| X.400    | X.400 email address: Use Only If Telecommunication Use Code Is NET |

Email address (ST)

Country code (NM)

Area/city code (NM)

Phone number (NM)

Extension (NM)

Any text (ST)



## **Appendix B -- HL7 Tables**

The following tables give valid values for fields in the segments defined above, in the cases where the field definitions reference an HL7 table number. The tables are considered to be part of the HL7 standard, but those tables designated as type User have values determined by VIIS.

| Type | Table | Name                       | Value  | Description                                 |
|------|-------|----------------------------|--------|---|
| HL7  | 0001  | <u>Sex</u>                 |        |   |
|      | 0001  |                            | F      | Female                                      |
|      | 0001  |                            | M      | Male  |
|      | 0001  |                            | O      | Other                                       |
|      | 0001  |                            | U      | Unknown                                     |
| HL7  | 0003  | <u>Event Type</u>          |        |   |
|      | 0003  |                            | A31    | ADT/ACK - Update patient information        |
|      | 0003  |                            | V04    | VXU - Unsolicited vaccination record update |
| HL7  | 0004  | <u>Patient class</u>       |        |   |
|      | 0004  |                            | E      | Emergency                                   |
|      | 0004  |                            | I      | Inpatient                                   |
|      | 0004  |                            | O      | Outpatient                                  |
|      | 0004  |                            | P      | Preadmit                                    |
|      | 0004  |                            | R      | Recurring                                   |
|      | 0004  |                            | B      | Obstetrics                                  |
| HL7  | 0005  | <u>Race</u>                |        |   |
|      | 0005  |                            | 1002-5 | American Indian or Alaska Native            |
|      | 0005  |                            | 2028-9 | Asian                                       |
|      | 0005  |                            | 2076-8 | Native Hawaiian or Other Pacific Islander   |
|      | 0005  |                            | 2054-5 | Black or African-American                   |
|      | 0005  |                            | 2106-3 | White                                       |
|      | 0005  |                            | 2135-2 | Hispanic or Latino                          |
|      | 0005  |                            | 2186-5 | Not Hispanic or Latino                      |
|      | 0005  |                            | 2131-1 | Other Race                                  |
|      | 0005  |                            | Null   | Unknown                                     |
| HL7  | 0008  | <u>Acknowledgment Code</u> |        |   |
|      | 0008  |                            | AA     | Application Accept                          |
|      | 0008  |                            | AE     | Application Error                           |
|      | 0008  |                            | AR     | Application Reject                          |
| User | 0063  | <u>Relationship</u>        |        |   |
|      | 0063  |                            | ASC    | Associate                                   |
|      | 0063  |                            | BRO    | Brother                                     |
|      | 0063  |                            | CGV    | Care giver                                  |
|      | 0063  |                            | CHD    | Child                                       |
|      | 0063  |                            | DEP    | Handicapped dependent                       |
|      | 0063  |                            | DOM    | Life partner                                |
|      | 0063  |                            | EMC    | Emergency contact                           |
|      | 0063  |                            | EME    | Employee                                    |
|      | 0063  |                            | EMR    | Employer                                    |
|      | 0063  |                            | EXF    | Extended family                             |
|      | 0063  |                            | FCH    | Foster Child                                |
|      | 0063  |                            | FND    | Friend                                      |
|      | 0063  |                            | FTH    | Father                                      |
|      | 0063  |                            | GCH    | Grandchild                                  |
|      | 0063  |                            | GRD    | Guardian                                    |
|      | 0063  |                            | GRP    | Grandparent                                 |
|      | 0063  |                            | MGR    | Manager                                     |
|      | 0063  |                            | MTH    | Mother                                      |
|      | 0063  |                            | NCH    | Natural child                               |
|      | 0063  |                            | NON    | None  |
|      | 0063  |                            | OAD    | Other adult                                 |
|      | 0063  |                            | OTH    | Other                                       |
|      | 0063  |                            | OWN    | Owner                                       |
|      | 0063  |                            | PAR    | Parent                                      |
|      | 0063  |                            | SCH    | Stepchild                                   |

| Type | Table | Name  | Value | Description  |
|------|-------|---|-------|--|
|      | 0063  |   | SEL   | Self   |
|      | 0063  |   | SIB   | Sibling  |
|      | 0063  |   | SIS   | Sister   |
|      | 0063  |   | SPO   | Spouse   |
|      | 0063  |   | TRA   | Trainer  |
|      | 0063  |   | UNK   | Unknown  |
|      | 0063  |   | WRD   | Ward of court  |
| HL7  | 0064  | <u>Financial class</u>                              |       |  |
|      | 0064  |   | V00   | VFC eligibility not determined/unknown                                   |
|      | 0064  |   | V01   | Not VFC eligible – (Insured, Vaccines Covered)                           |
|      | 0064  |   | V02   | VFC eligible – Medicaid/Medicaid Managed Care                            |
|      | 0064  |   | V03   | VFC eligible – Uninsured   |
|      | 0064  |   | V04   | VFC eligible – American Indian/Alaskan Native                            |
|      | 0064  |   | V05   | VFC eligible – Federally Qualified Health Center Patient (under-insured) |
|      | 0064  |   | V06   | VFC eligible – Medicaid HMO  |
|      | 0064  |   | CH00  | Not VFC eligible - FAMIS   |
|      | 0064  |   | IS01  | VFC eligible – Underinsured at pvt Facility/Public Hospital/Health Dept  |
| HL7  | 0076  | <u>Message Type</u>                                 |       |  |
|      | 0076  |   | ACK   | General acknowledgment message   |
|      | 0076  |   | ADR   | ADT response   |
|      | 0076  |   | ADT   | ADT message  |
|      | 0076  |   | QCK   | Query general acknowledgment   |
|      | 0076  |   | VXQ   | Query for vaccination record   |
|      | 0076  |   | VXX   | Vaccination query response with multiple PID matches                     |
|      | 0076  |   | VXR   | Vaccination query record response  |
|      | 0076  |   | VXU   | Unsolicited vaccination record update                                    |
|      | 0076  |   | ORU   | Unsolicited observation results  |
| HL7  | 0085  | <u>Observation result status codes</u>              |       |  |
|      | 0085  |   | O     | Order detail description only  |
| HL7  | 0103  | <u>Processing ID</u>                                |       |  |
|      | 0103  |   | P     | Production   |
| HL7  | 0104  | <u>Version ID</u>                                   |       |  |
|      | 0104  |   | 2.3.1 | Release 2.3.1 1999   |
|      | 0104  |   | 2.4   | Release 2.4 2000   |
| HL7  | 0136  | <u>Yes/No Indicator</u>                             |       |  |
|      | 0136  |   | Y     | Yes  |
|      | 0136  |   | N     | No   |
| HL7  | 0155  | <u>Accept/Application Acknowledgment Conditions</u> |       |  |
|      | 0155  |   | ER    | Error/reject conditions only   |
| HL7  | 0162  | <u>Route of Administration</u>                      |       |  |
|      | 0162  |   | ID    | Intradermal  |
|      | 0162  |   | IM    | Intramuscular  |
|      | 0162  |   | IN    | Intranasal   |
|      | 0162  |   | IV    | Intravenous  |
|      | 0162  |   | PO    | Oral   |
|      | 0162  |   | SC    | Subcutaneous   |
|      | 0162  |   | TD    | Transdermal  |
|      | 0162  |   | MP    | Multiple Puncture (Small Pox)  |
| HL7  | 0163  | <u>Administrative Site</u>                          |       |  |
|      | 0163  |   | LT    | Left Thigh   |
|      | 0163  |   | LA    | Left Arm   |
|      | 0163  |   | LD    | Left Deltoid   |
|      | 0163  |   | LG    | Left Gluteus Medius  |

| Type | Table | Name  | Value  | Description  |
|------|-------|---|--------|--|
|      | 0163  |   | LVL    | Left Vastus Lateralis  |
|      | 0163  |   | LLFA   | Left Lower Forearm   |
|      | 0163  |   | RA     | Right Arm  |
|      | 0163  |   | RT     | Right Thigh  |
|      | 0163  |   | RVL    | Right Vastus Lateralis   |
|      | 0163  |   | RG     | Right Gluteus Medius   |
|      | 0163  |   | RD     | Right Deltoid  |
|      | 0163  |   | RLFA   | Right Lower Forearm  |
| HL7  | 0189  | <u>Ethnic Group</u>                           |        |  |
|      | 0189  |   | 2135-2 | Hispanic   |
|      | 0189  |   | 2186-5 | Non-Hispanic   |
|      | 0189  |   | Null   | Unknown  |
| HL7  | 0203  | <u>Identifier Type</u>                        |        |  |
|      | 0203  |   | BR     | Birth Registry Number  |
|      | 0203  |   | MA     | Medicaid Number  |
|      | 0203  |   | MC     | Medicare Number  |
|      | 0203  |   | MR     | Medical Record Number  |
|      | 0203  |   | PI     | Patient Internal Identifier  |
|      | 0203  |   | PN     | Person Number  |
|      | 0203  |   | PRN    | Provider Number  |
|      | 0203  |   | PT     | Patient External Identifier  |
|      | 0203  |   | RRI    | Regional Registry ID   |
|      | 0203  |   | SR     | State Registry Identifier  |
|      | 0203  |   | SS     | Social Security Number   |
| User | 0212  | <u>Nationality</u>                            |        |  |
|      | 0212  |   | CA     | Canada   |
|      | 0212  |   | US     | United States of America   |
| User | 0215  | <u>Publicity Code</u>                         |        |  |
|      | 0215  |   | 01     | No reminder/recall   |
|      | 0215  |   | 02     | Yes reminder/recall – any method   |
| HL7  | 0227  | <u>Manufacturers of vaccines (code = MVX)</u> |        |  |
|      | 0227  |   | AB     | Abbott Laboratories ( <i>Ross Products Division</i> )                              |
|      | 0227  |   | ACA    | ACAMBIS  |
|      | 0227  |   | AD     | Adams Laboratories   |
|      | 0227  |   | ALP    | Alpha Therapeutic Corporation  |
|      | 0227  |   | AR     | Armour (Inactive use AVB)  |
|      | 0227  |   | AVB    | Aventis Behring L.L.C. ( <i>Centeon and Armour Pharmaceutical</i> )                |
|      | 0227  |   | AVI    | Aviron   |
|      | 0227  |   | BA     | Baxter Healthcare Corporation (Inactive use BAH)                                   |
|      | 0227  |   | BAH    | Baxter Healthcare Corporation ( <i>Hyland, Immuno Intl. AG, and N. Amer. Vac</i> ) |
|      | 0227  |   | BAY    | Bayer (Including Miles And Cutter)   |
|      | 0227  |   | BP     | Berna Products (Inactive use BPC)  |
|      | 0227  |   | BPC    | Berna ( <i>Includes Swiss Serum And Vaccine Institute Berne (Vib)</i> )            |
|      | 0227  |   | CEN    | Centeon (Inactive use AVB)   |
|      | 0227  |   | CHI    | Chiron Corporation   |
|      | 0227  |   | CMP    | Celltech Medeva Pharmaceuticals (Inactive use PWJ)                                 |
|      | 0227  |   | CNJ    | Cangene Corporation  |
|      | 0227  |   | CON    | Connaught (Inactive use PMC)   |
|      | 0227  |   | CSL    | CSL Biotherapies, Inc.   |
|      | 0227  |   | DVC    | DynPort Vaccine Company, LLC   |
|      | 0227  |   | EVN    | Evans Medical Limited (Inactive use PWJ)   |
|      | 0227  |   | GEO    | GeoVax Labs, Inc.  |
|      | 0227  |   | GRE    | Greer Laboratories Inc.  |

| Type | Table | Name                                  | Value | Description  |
|------|-------|---------------------------------------|-------|--|
|      | 0227  |                                       | IAG   | Immuno International Ag (Inactive use BAH)                               |
|      | 0227  |                                       | IM    | Merieux (Inactive use PMC)   |
|      | 0227  |                                       | INT   | Intercell Biomedical   |
|      | 0227  |                                       | IUS   | Immuno-U.S., Inc.  |
|      | 0227  |                                       | JPN   | Osaka University (Biken)   |
|      | 0227  |                                       | KGC   | Korea Green Cross Corporation  |
|      | 0227  |                                       | LED   | Lederle (Inactive use WAL)   |
|      | 0227  |                                       | MA    | Massachusetts Public Health Biologic Lab (Inactive use MBL)              |
|      | 0227  |                                       | MBL   | Massachusetts Biologics Laboratories                                     |
|      | 0227  |                                       | MED   | Medimmune, Inc.  |
|      | 0227  |                                       | MIL   | Miles (Inactive use BAY)   |
|      | 0027  |                                       | MIP   | Bioport Corporation (formerly Michigan Biologic Prod Inst.)              |
|      | 0227  |                                       | MSD   | Merck & Co., Inc.  |
|      | 0227  |                                       | NAB   | NABI (formerly North American Biologicals)                               |
|      | 0227  |                                       | NAV   | North American Vaccine, Inc. (Inactive use BAH)                          |
|      | 0227  |                                       | NOV   | Novartis Pharmaceutical Corp. ( <i>Ciba-Geigy and Sandoz</i> )           |
|      | 0227  |                                       | NVX   | Novavax, Inc   |
|      | 0227  |                                       | NYB   | New York Blood Center  |
|      | 0227  |                                       | OTC   | Organon Teknika Corporation  |
|      | 0227  |                                       | ORT   | Ortho-Clinical Diagnostics (formerly Ortho Diagnostic Systems, Inc.)     |
|      | 0227  |                                       | PMC   | Aventis Pasteur ( <i>Connaught and Pasteur Merieux</i> )                 |
|      | 0227  |                                       | PD    | Parkedale Pharmaceuticals (formerly Parke-Davis)                         |
|      | 0227  |                                       | PRX   | Praxis Biologics (Inactive use WAL)                                      |
|      | 0227  |                                       | PWJ   | Powerject Pharmaceuticals ( <i>Celltech Medeva and Evans Medical</i> )   |
|      | 0227  |                                       | SA    | United States Army Medical Research and Material Command                 |
|      | 0227  |                                       | SCL   | Sclavo, Inc.   |
|      | 0227  |                                       | SI    | Swiss Serum and Vaccine Inst. (Inactive use BPC)                         |
|      | 0227  |                                       | SKB   | GlaxoSmithKline ( <i>SmithKline Beecham and Glaxo Wellcome</i> )         |
|      | 0227  |                                       | SOL   | Solvay Pharmaceuticals   |
|      | 0227  |                                       | TAL   | Talecris Biotherapeutics (includes Bayer Biologicals)                    |
|      | 0227  |                                       | USA   | Us Army Med Research   |
|      | 0227  |                                       | VXG   | VaxGen   |
|      | 0227  |                                       | WA    | Wyeth-Ayerst (Inactive use WAL)  |
|      | 0227  |                                       | WAL   | Wyeth-Ayerst ( <i>Lederle and Praxis</i> )                               |
|      | 0227  |                                       | ZLB   | ZLB Behring (includes Aventis Behring and Armour Pharmaceutical Company) |
|      | 0227  |                                       | OTH   | Other manufacturer   |
|      | 0227  |                                       | UNK   | Unknown  |
| User | 0289  | <u>County/parish (Wisconsin only)</u> |       |  |
|      | 0289  |                                       | VA001 | Accomack   |
|      | 0289  |                                       | VA003 | Albemarle  |
|      | 0289  |                                       | VA005 | Alleghany  |
|      | 0289  |                                       | VA007 | Amelia   |
|      | 0289  |                                       | VA009 | Amherst  |
|      | 0289  |                                       | VA011 | Appomattox   |
|      | 0289  |                                       | VA013 | Arlington  |
|      | 0289  |                                       | VA015 | Augusta  |
|      | 0289  |                                       | VA017 | Bath   |
|      | 0289  |                                       | VA019 | Bedford  |
|      | 0289  |                                       | VA021 | Bland  |
|      | 0289  |                                       | VA023 | Botetourt  |
|      | 0289  |                                       | VA025 | Brunswick  |

| Type | Table | Name | Value | Description    |
|------|-------|------|-------|----------------|
|      | 0289  |      | VA027 | Buchanan       |
|      | 0289  |      | VA029 | Buckingham     |
|      | 0289  |      | VA031 | Campbell       |
|      | 0289  |      | VA033 | Caroline       |
|      | 0289  |      | VA035 | Carroll        |
|      | 0289  |      | VA036 | Charles City   |
|      | 0289  |      | VA037 | Charlotte      |
|      | 0289  |      | VA041 | Chesterfield   |
|      | 0289  |      | VA043 | Clarke         |
|      | 0289  |      | VA045 | Craig          |
|      | 0289  |      | VA047 | Culpeper       |
|      | 0289  |      | VA049 | Cumberland     |
|      | 0289  |      | VA051 | Dickenson      |
|      | 0289  |      | VA053 | Dinwiddie      |
|      | 0289  |      | VA057 | Essex          |
|      | 0289  |      | VA059 | Fairfax        |
|      | 0289  |      | VA061 | Fauquier       |
|      | 0289  |      | VA063 | Floyd          |
|      | 0289  |      | VA065 | Fluvanna       |
|      | 0289  |      | VA067 | Franklin       |
|      | 0289  |      | VA069 | Frederick      |
|      | 0289  |      | VA071 | Giles          |
|      | 0289  |      | VA073 | Gloucester     |
|      | 0289  |      | VA075 | Goochland      |
|      | 0289  |      | VA077 | Grayson        |
|      | 0289  |      | VA079 | Greene         |
|      | 0289  |      | VA081 | Greensville    |
|      | 0289  |      | VA083 | Halifax        |
|      | 0289  |      | VA085 | Hanover        |
|      | 0289  |      | VA087 | Henrico        |
|      | 0289  |      | VA089 | Henry          |
|      | 0289  |      | VA091 | Highland       |
|      | 0289  |      | VA093 | Isle of Wight  |
|      | 0289  |      | VA095 | James City     |
|      | 0289  |      | VA097 | King and Queen |
|      | 0289  |      | VA099 | King George    |
|      | 0289  |      | VA101 | King William   |
|      | 0289  |      | VA103 | Lancaster      |
|      | 0289  |      | VA105 | Lee            |
|      | 0289  |      | VA107 | Loudoun        |
|      | 0289  |      | VA109 | Louisa         |
|      | 0289  |      | VA111 | Lunenburg      |
|      | 0289  |      | VA113 | Madison        |
|      | 0289  |      | VA115 | Mathews        |
|      | 0289  |      | VA117 | Mecklenburg    |
|      | 0289  |      | VA119 | Middlesex      |
|      | 0289  |      | VA121 | Montgomery     |
|      | 0289  |      | VA125 | Nelson         |
|      | 0289  |      | VA127 | New Kent       |
|      | 0289  |      | VA131 | Northampton    |
|      | 0289  |      | VA133 | Northumberland |
|      | 0289  |      | VA135 | Nottoway       |
|      | 0289  |      | VA137 | Orange         |
|      | 0289  |      | VA139 | Page           |
|      | 0289  |      | VA141 | Patrick        |

| Type | Table | Name | Value | Description             |
|------|-------|------|-------|-------------------------|
|      | 0289  |      | VA143 | Pittsylvania            |
|      | 0289  |      | VA145 | Powhatan                |
|      | 0289  |      | VA147 | Prince Edward           |
|      | 0289  |      | VA149 | Prince George           |
|      | 0289  |      | VA153 | Prince William          |
|      | 0289  |      | VA155 | Pulaski                 |
|      | 0289  |      | VA157 | Rappahannock            |
|      | 0289  |      | VA159 | Richmond                |
|      | 0289  |      | VA161 | Roanoke                 |
|      | 0289  |      | VA163 | Rockbridge              |
|      | 0289  |      | VA165 | Rockingham              |
|      | 0289  |      | VA167 | Russell                 |
|      | 0289  |      | VA169 | Scott                   |
|      | 0289  |      | VA171 | Shenandoah              |
|      | 0289  |      | VA173 | Smyth                   |
|      | 0289  |      | VA175 | Southampton             |
|      | 0289  |      | VA177 | Spotsylvania            |
|      | 0289  |      | VA179 | Stafford                |
|      | 0289  |      | VA181 | Surry                   |
|      | 0289  |      | VA183 | Sussex                  |
|      | 0289  |      | VA185 | Tazewell                |
|      | 0289  |      | VA187 | Warren                  |
|      | 0289  |      | VA191 | Washington              |
|      | 0289  |      | VA193 | Westmoreland            |
|      | 0289  |      | VA195 | Wise                    |
|      | 0289  |      | VA197 | Wythe                   |
|      | 0289  |      | VA199 | York                    |
|      | 0289  |      | VA510 | Alexandria (city)       |
|      | 0289  |      | VA515 | Bedford (city)          |
|      | 0289  |      | VA520 | Bristol (city)          |
|      | 0289  |      | VA530 | Buena Vista (city)      |
|      | 0289  |      | VA540 | Charlottesville (city)  |
|      | 0289  |      | VA550 | Chesapeake (city)       |
|      | 0289  |      | VA560 | Clifton Forge (city)    |
|      | 0289  |      | VA570 | Colonial Heights (city) |
|      | 0289  |      | VA580 | Covington (city)        |
|      | 0289  |      | VA590 | Danville (city)         |
|      | 0289  |      | VA595 | Emporia (city)          |
|      | 0289  |      | VA600 | Fairfax (city)          |
|      | 0289  |      | VA610 | Falls Church (city)     |
|      | 0289  |      | VA620 | Franklin (city)         |
|      | 0289  |      | VA630 | Fredericksburg (city)   |
|      | 0289  |      | VA640 | Galax (city)            |
|      | 0289  |      | VA650 | Hampton (city)          |
|      | 0289  |      | VA660 | Harrisonburg (city)     |
|      | 0289  |      | VA670 | Hopewell (city)         |
|      | 0289  |      | VA678 | Lexington (city)        |
|      | 0289  |      | VA680 | Lynchburg (city)        |
|      | 0289  |      | VA683 | Manassas (city)         |
|      | 0289  |      | VA685 | Manassas Park (city)    |
|      | 0289  |      | VA690 | Martinsville (city)     |
|      | 0289  |      | VA700 | Newport News (city)     |
|      | 0289  |      | VA710 | Norfolk (city)          |
|      | 0289  |      | VA720 | Norton (city)           |
|      | 0289  |      | VA730 | Petersburg (city)       |

| Type | Table  | Name                                   | Value  | Description   |
|------|--------|--|--------|---|
|      | 0289   |  | VA735  | Poquoson (city)   |
|      | 0289   |  | VA740  | Portsmouth (city)   |
|      | 0289   |  | VA750  | Radford (city)  |
|      | 0289   |  | VA760  | Richmond (city)   |
|      | 0289   |  | VA770  | Roanoke (city)  |
|      | 0289   |  | VA775  | Salem (city)  |
|      | 0289   |  | VA780  | South Boston (city)   |
|      | 0289   |  | VA790  | Staunton (city)   |
|      | 0289   |  | VA800  | Suffolk (city)  |
|      | 0289   |  | VA810  | Virginia Beach (city)   |
|      | 0289   |  | VA820  | Waynesboro (city)   |
|      | 0289   |  | VA830  | Williamsburg (city)   |
|      | 0289   |  | VA840  | Winchester (city)   |
|      |        |  |        |   |
| NIP  | NIP001 | <u>Immunization Information Source</u> |        |   |
|      | NIP001 |  | 00     | New Immunization Record   |
|      | NIP001 |  | 01     | Historical Information  |
| NIP  | NIP002 | <u>Substance Refusal Reason</u>        |        |   |
|      | NIP002 |  | 00     | Parental Refusal  |
|      | NIP002 |  | 01     | Religious Exemption   |
| NIP  | NIP004 | <u>Contraindications, Precautions</u>  |        |   |
|      | NIP004 |  | 01     | Recipient condition-unspecified   |
|      | NIP004 |  | 02     | Household condition-unspecified   |
|      | NIP004 |  | 03     | Allergy to baker's yeast (anaphylactic)   |
|      | NIP004 |  | 04     | Allergy to egg ingestion (anaphylactic)   |
|      | NIP004 |  | 05     | Allergy to gelatin (anaphylactic)   |
|      | NIP004 |  | 06     | Allergy to neomycin (anaphylactic)  |
|      | NIP004 |  | 07     | Allergy to streptomycin (anaphylactic)  |
|      | NIP004 |  | 08     | Allergy to thimerosal (anaphylactic)  |
|      | NIP004 |  | 09     | Allergy to previous dose of this vaccine or to any of its unlisted vaccine components (anaphylactic)      |
|      | NIP004 |  | 10     | Anaphylactic (life-threatening) reaction of previous doses of this vaccine                                |
|      | NIP004 |  | 11     | Collapse or shock like state within 48 hours of previous dose of DTP/DTaP                                 |
|      | NIP004 |  | 12     | Convulsions (fits, seizures) within 3 days of previous dose of DTP/DTaP                                   |
|      | NIP004 |  | 13     | Persistent, inconsolable crying lasting 3 hours within 48 hours of previous dose of DTP/DTaP              |
|      | NIP004 |  | 14     | Current diarrhea, moderate to severe  |
|      | NIP004 |  | 15     | Encephalopathy within 7 days of previous dose of DTP  |
|      | NIP004 |  | 16     | Current fever with moderate-to-severe illness   |
|      | NIP004 |  | 17     | Fever of 40.5 C (105 F) within 48 hours of previous dose of DTP/DTaP                                      |
|      | NIP004 |  | 18     | Guillain-Barre Syndrome (GBS) within 6 weeks after vaccine containing DTP/DTaP                            |
|      | NIP004 |  | 19     | HIV infection (in household contact)  |
|      | NIP004 |  | 20     | HIV infection (in recipient)  |
|      | NIP004 |  | 21     | Current acute illness, moderate to severe (with or without fever) (e.g. diarrhea, otitis media, vomiting) |
|      | NIP004 |  | 22     | Chronic illness (e.g. chronic gastrointestinal disease)   |
|      | NIP004 |  | 23     | IG/Blood product received   |
|      | NIP004 |  | 24     | Immunity: diphtheria  |
|      | NIP004 |  | 25     | Immunity: Haemophilus influenzae type B (Hib)   |
|      | NIP004 |  | HEPA_I | Immunity: hepatitis A   |
|      | NIP004 |  | 26     | Immunity: Hep B   |
|      | NIP004 |  | 27     | Immunity: measles   |
|      | NIP004 |  | 28     | Immunity: mumps   |
|      | NIP004 |  | 29     | Immunity: pertussis   |
|      | NIP004 |  | 30     | Immunity: poliovirus  |



| Type | Table  | Name | Value  | Description  |
|------|--------|------|--------|--|
|      | NIP004 |      | 31     | Immunity: rubella  |
|      | NIP004 |      | 32     | Immunity: tetanus  |
|      | NIP004 |      | 33     | Immunity: varicella  |
|      | NIP004 |      | 33A    | History of Chicken Pox/Varicella   |
|      | NIP004 |      | 34     | Immunodeficiency (family history)  |
|      | NIP004 |      | 35     | Immunodeficiency (household contact)   |
|      | NIP004 |      | 36     | Immunodeficiency (in recipient)  |
|      | NIP004 |      | 37     | Neurologic disorders, underlying (including seizure disorders, cerebral palsy, and developmental delay)      |
|      | NIP004 |      | 38     | Otitis media (ear infection) moderate to severe (with or without fever)                                      |
|      | NIP004 |      | 39     | Pregnancy (in recipient)   |
|      | NIP004 |      | 40     | Thrombocytopenia   |
|      | NIP004 |      | 41     | Thrombocytopenia purpura (history)   |
|      | NIP004 |      | 44     | Allergy to Latex (anaphylactic)  |
|      | NIP004 |      | 45     | Immunity: Rabies   |
|      | NIP004 |      | 50     | History of: Vaccinia (Small Pox)   |
|      | NIP004 |      | 51     | History of: Yellow Fever   |
|      | NIP004 |      | 52     | History of: Pneumococcal   |
|      | NIP004 |      | 53     | History of: Rotavirus  |
|      | NIP004 |      | 54     | History of: Meningococcal  |
|      | NIP004 |      | 55     | History of: Human papilloma virus  |
|      | NIP004 |      | 56     | History of: Viral hepatitis, Type A  |
|      | NIP004 |      | 57     | History of: Anthrax  |
|      | NIP004 |      | 58     | History of: Typhoid  |
|      | NIP004 |      | 59     | History of: Japanese Encephalitis  |
|      | NIP004 |      | 61     | Previous history of intussusception  |
|      | NIP004 |      | 62     | History of Arthus hypersensitivity reaction to a tetanus-containing vaccine administration < 10 yrs previous |
|      | NIP004 |      | 63     | Member of special group  |
|      | NIP004 |      | 64     | Rash within 14 days of dose  |
|      | NIP004 |      | 65     | Intussusception within 30 days of dose   |
|      | NIP004 |      | 66     | Allergy to alum (anaphylactic)   |
|      | NIP004 |      | 67     | Allergy to Polymyrix B   |
|      | NIP004 |      | 68     | Allergy to proteins of rodent or neural (anaphylactic)   |
|      | NIP004 |      | 69     | Allergy to phenoxyethanol  |
|      | NIP004 |      | HEPA 1 | Immunity: Hep A  |
|      | NIP004 |      | ME01   | Medical Exemption-All Childhood Vaccines   |
|      | NIP004 |      | ME02   | Medical Exemption-DTaP   |
|      | NIP004 |      | ME03   | Medical Exemption-MMR  |
|      | NIP004 |      | ME04   | Medical Exemption-Varicella  |
|      | NIP004 |      | P1     | Refusal to DT  |
|      | NIP004 |      | P10    | Refusal of Smallpox  |
|      | NIP004 |      | P2     | Refusal of DT/aP   |
|      | NIP004 |      | P3     | Refusal of HepB  |
|      | NIP004 |      | P4     | Refusal of Hib   |
|      | NIP004 |      | P5     | Refusal of MMR   |
|      | NIP004 |      | P6     | Refusal of Pneumococcal  |
|      | NIP004 |      | P7     | Refusal of Polio   |
|      | NIP004 |      | P8     | Refusal of Td  |
|      | NIP004 |      | P9     | Refusal of Varicella   |
|      | NIP004 |      | PALL   | Refusal of All Childhood Vaccines  |
|      | NIP004 |      | PB     | Refusal of Hep A   |
|      | NIP004 |      | PC     | Refusal of Influenza   |
|      | NIP004 |      | PD     | Refusal of HPV   |
|      | NIP004 |      | PE     | Refusal of Meningitis  |

| Type | Table  | Name | Value  | Description   |
|------|--------|------|--------|---|
|      | NIP004 |      | PF     | Vaccine Not Available - DT                              |
|      | NIP004 |      | PG     | Vaccine Not Available - DTaP                            |
|      | NIP004 |      | PH     | Vaccine Not Available - Hep A                           |
|      | NIP004 |      | PI     | Vaccine Not Available - Hep B                           |
|      | NIP004 |      | PJ     | Vaccine Not Available - Hib                             |
|      | NIP004 |      | PK     | Vaccine Not Available - HPV                             |
|      | NIP004 |      | PL     | Vaccine Not Available - Meningitis                      |
|      | NIP004 |      | PM     | Vaccine Not Available - MMR                             |
|      | NIP004 |      | PN     | Vaccine Not Available - Pneumococcal                    |
|      | NIP004 |      | PO     | Vaccine Not Available - Polio                           |
|      | NIP004 |      | PP     | Vaccine Not Available - Td                              |
|      | NIP004 |      | PQ     | Vaccine Not Available - Varicella                       |
|      | NIP004 |      | PR     | Vaccine Not Available - Influenza                       |
|      | NIP004 |      | PS     | Religious Exemption - All Childhood                     |
|      | NIP004 |      | PT     | Refusal of Tdap   |
|      | NIP004 |      | PU     | Refusal of Zoster                                       |
|      | NIP004 |      | PV     | Vaccine not available: Tdap                             |
|      | NIP004 |      | R1     | Clinician has decided to repeat the DTAP series         |
|      | NIP004 |      | R2     | Clinician has decided to repeat the Hep B series        |
|      | NIP004 |      | R3     | Clinician has decided to repeat the HIB series          |
|      | NIP004 |      | R4     | Clinician has decided to repeat the Polio series        |
|      | NIP004 |      | R5     | Clinician has decided to repeat the MMR series          |
|      | NIP004 |      | R6     | Clinician has decided to repeat the Pneumococcal series |
|      | NIP004 |      | R7     | Clinician has decided to repeat the Varicella series    |
|      | NIP004 |      | RABEXP | Client has been exposed to rabies                       |

| Type | Table   | Name                             | Value        | Description  |
|------|---------|----------------------------------|--------------|--|
|      | NIP004  |                                  | 40           | Thrombocytopenia   |
|      | NIP004  |                                  | 41           | Thrombocytopenic purpura (history)                                   |
| NIP  | NIP005  | <u>Event Consequence</u>         |              |  |
|      | NIP005  |                                  | D            | Patient Died   |
|      | NIP005  |                                  | L            | Life threatening illness   |
|      | NIP005  |                                  | E            | Required emergency room/doctor visit                                 |
|      | NIP005  |                                  | H            | Required hospitalization   |
|      | NIP005  |                                  | P            | Resulted in prolongation of hospitalization                          |
|      | NIP005  |                                  | J            | Resulted in permanent disability                                     |
| NIP  | NIP006  | <u>Patient Registry Status</u>   |              |  |
|      | NIP006  |                                  | A            | Active   |
|      | NIP006  |                                  | N            | Inactive   |
|      | NIP006  |                                  | P            | Permanently inactive (dead)  |
| VIIS | VIIS001 | <u>Reaction Codes</u>            |              |  |
|      | VIIS001 |                                  | PERTCONT     | Pertussis allergic reaction  |
|      | VIIS001 |                                  | REDNESS      | Redness or swelling at vaccination site                              |
|      | VIIS001 |                                  | TETCONT      | Tetanus allergic reaction  |
|      | VIIS001 |                                  | HYPOTON      | Hypotonic-hyporesponsive collapse within 48 hours of immunization    |
|      | VIIS001 |                                  | SEIZURE      | Seizure occurring within 3 days                                      |
|      | VIIS001 |                                  | CRYING       | Persistent crying lasting >= 3 hours within 48 hours of immunization |
|      | VIIS001 |                                  | FEVER105     | Temperature >= 105 (40.5 C) within 48 hours of immunization          |
| VIIS | WVGC    | <u>Vaccine Group Code (WVGC)</u> |              |  |
|      | WVGC    |                                  | Adeno        | Adeno  |
|      | WVGC    |                                  | Anthrax      | Anthrax  |
|      | WVGC    |                                  | BCG          | BCG  |
|      | WVGC    |                                  | Cholera      | Cholera  |
|      | WVGC    |                                  | Diphtheria   | Diphtheria Antitoxin   |
|      | WVGC    |                                  | DTP/aP       | Diphtheria, Tetanus, Acellular Pertussis                             |
|      | WVGC    |                                  | Encephalitis | Encephalitis   |
|      | WVGC    |                                  | Flu H1N1-09  | Novel Influenza-H1N1-09 all formulations                             |
|      | WVGC    |                                  | HepA         | Hepatitis A  |
|      | WVGC    |                                  | HepB         | Hepatitis B  |
|      | WVGC    |                                  | Hib          | Hib  |
|      | WVGC    |                                  | HPV          | Human Papilloma Virus  |
|      | WVGC    |                                  | Ig           | Ig   |
|      | WVGC    |                                  | Influenza    | Influenza  |
|      | WVGC    |                                  | Lyme         | Lyme   |
|      | WVGC    |                                  | Measles      | Measles Virus Vaccine  |
|      | WVGC    |                                  | MMR          | Measles, Mumps, Rubella  |
|      | WVGC    |                                  | Meningo      | Meningitis   |
|      | WVGC    |                                  | Mumps        | Mumps Virus Vaccine  |
|      | WVGC    |                                  | Plague       | Plague   |
|      | WVGC    |                                  | Pneumococcal | Pneumonia Conjugate  |
|      | WVGC    |                                  | Pneumo-Poly  | Pneumonia Polysaccharide   |
|      | WVGC    |                                  | Polio        | Poliomyelitis  |
|      | WVGC    |                                  | Rabies       | Rabies   |
|      | WVGC    |                                  | Rotavirus    | Rotavirus  |
|      | WVGC    |                                  | Rubella      | Rubella Virus Vaccine  |
|      | WVGC    |                                  | Tetanus      | Tetanus Diphtheria   |
|      | WVGC    |                                  | Td           | Tetanus Diphtheria   |
|      | WVGC    |                                  | Typhoid      | Typhoid  |
|      | WVGC    |                                  | Smallpox     | Vaccinia   |
|      | WVGC    |                                  | Varicella    | Varicella  |

| Type | Table | Name                             | Value                       | Description                           |
|------|-------|----------------------------------|-----------------------------|---------------------------------------|
|      | WVGC  |                                  | Yellow Fever                | Yellow Fever                          |
|      | WVGC  |                                  | Zoster                      | Zoster (shingles), live               |
| VIIS | WVTN  | <u>Vaccine Trade Name (WVTN)</u> |                             |                                       |
|      | WVTN  |                                  | ACAM2000                    | Smallpox                              |
|      | WVTN  |                                  | Acel-Imune                  | DTaP                                  |
|      | WVTN  |                                  | ActHib                      | Hib-PRP-T                             |
|      | WVTN  |                                  | Adeno T4                    | Adeno T4                              |
|      | WVTN  |                                  | Adeno T7                    | Adeno T7                              |
|      | WVTN  |                                  | Afluria                     | Influenza                             |
|      | WVTN  |                                  | Afluria, Preservative Free  | Preservative-Free Influenza           |
|      | WVTN  |                                  | Agriflu                     | Preservative-Free Influenza           |
|      | WVTN  |                                  | Anthrax                     | Anthrax                               |
|      | WVTN  |                                  | Attenuvax                   | Measles                               |
|      | WVTN  |                                  | BabyBIG                     | Botulism                              |
|      | WVTN  |                                  | BayTet                      | Tlg                                   |
|      | WVTN  |                                  | BCG-Cancer                  | BCG-BC                                |
|      | WVTN  |                                  | BCG-TB                      | BCG-TB                                |
|      | WVTN  |                                  | Biavax II                   | Rubella-Mumps                         |
|      | WVTN  |                                  | BIG                         | Botulism                              |
|      | WVTN  |                                  | Botulinum-antitoxin         | Botulinum-antitoxin                   |
|      | WVTN  |                                  | Botulism                    | Botulism                              |
|      | WVTN  |                                  | Certiva                     | DTaP                                  |
|      | WVTN  |                                  | Cervarix                    | HPV, Bivalent                         |
|      | WVTN  |                                  | Cholera-I                   | Cholera-Inject                        |
|      | WVTN  |                                  | Cholera-O                   | Cholera-Oral                          |
|      | WVTN  |                                  | CMV-IgIV                    | CMV-IgIV                              |
|      | WVTN  |                                  | Comvax                      | HepB-Hib                              |
|      | WVTN  |                                  | DAPTACEL                    | DTaP,5 pertussis antigens             |
|      | WVTN  |                                  | DECAVAC                     | Td                                    |
|      | WVTN  |                                  | Diphtheria                  | Diphtheria                            |
|      | WVTN  |                                  | Diphtheria-antitoxin        | Diphtheria-antitoxin                  |
|      | WVTN  |                                  | Dryvax                      | Smallpox                              |
|      | WVTN  |                                  | DT                          | DT-Peds                               |
|      | WVTN  |                                  | DTP                         | DTP                                   |
|      | WVTN  |                                  | Engerix-B Adult             | HepB-Adult                            |
|      | WVTN  |                                  | Engerix-B dialysis          | HepB-Dialysis 4 dose                  |
|      | WVTN  |                                  | Engerix-B Peds              | HepB-Peds                             |
|      | WVTN  |                                  | Flebogamma                  | IgIV                                  |
|      | WVTN  |                                  | Fluarix                     | Preservative-Free Influenza           |
|      | WVTN  |                                  | Flu-Deleted                 | FLU, NOS                              |
|      | WVTN  |                                  | Flu-Imune                   | Influenza                             |
|      | WVTN  |                                  | Flu-Mist                    | FLU-Nasal                             |
|      | WVTN  |                                  | Flu-Shield                  | Influenza                             |
|      | WVTN  |                                  | Fluogen                     | Influenza                             |
|      | WVTN  |                                  | FluLaval                    | Influenza                             |
|      | WVTN  |                                  | Fluvirin                    | Influenza                             |
|      | WVTN  |                                  | Fluvirin, Preservative-free | Preservative-Free Influenza           |
|      | WVTN  |                                  | Fluzone                     | Influenza                             |
|      | WVTN  |                                  | Fluzone, High-Dose          | Preservative-Free High-Dose Influenza |
|      | WVTN  |                                  | Fluzone, Preservative-free  | Preservative-Free Influenza           |
|      | WVTN  |                                  | Gardasil                    | HPV, Quadrivalent                     |
|      | WVTN  |                                  | Havrix-Adult                | HepA-Adult                            |
|      | WVTN  |                                  | Havrix-Peds 2 Dose          | HepA-Ped 2 Dose                       |

| Type | Table | Name | Value                  | Description   |
|------|-------|------|------------------------|---|
|      | WVTN  |      | Havrix-Peds 3 Dose     | HepA-Peds   |
|      | WVTN  |      | HBIG                   | HBIG  |
|      | WVTN  |      | Hib-TITER              | Hib-HbOC  |
|      | WVTN  |      | Hiberix                | Hib-PRP-T   |
|      | WVTN  |      | Ig                     | Ig  |
|      | WVTN  |      | IgIV                   | IgIV  |
|      | WVTN  |      | Imovax Rabies ID       | Rabies-ID   |
|      | WVTN  |      | Imovax Rabies IM       | Rabies-IM   |
|      | WVTN  |      | Infanrix               | DTaP  |
|      | WVTN  |      | IPOL                   | Polio-Inject  |
|      | WVTN  |      | Ixiaro                 | Japanese Encephalitis-IM                                |
|      | WVTN  |      | JE-Vax                 | Japanese Enceph - SC                                    |
|      | WVTN  |      | LYMERix                | Lyme  |
|      | WVTN  |      | M-R-VAX                | Measles-Rubella   |
|      | WVTN  |      | Measles                | Measles   |
|      | WVTN  |      | Measles-Rubella (MERU) | Measles-Rubella   |
|      | WVTN  |      | Menactra               | Meningococcal conjugate vaccine                         |
|      | WVTN  |      | MENOMUNE               | Meningococcal   |
|      | WVTN  |      | MENVEO                 | Meningococcal-MCV4                                      |
|      | WVTN  |      | Meruvax II             | Rubella   |
|      | WVTN  |      | MMR II                 | MMR   |
|      | WVTN  |      | MMRV                   | MMRV  |
|      | WVTN  |      | Mumps                  | Mumps   |
|      | WVTN  |      | Mumps-Rubella (MURU)   | Rubella-Mumps   |
|      | WVTN  |      | Mumpsvax               | Mumps   |
|      | WVTN  |      | OmniHib                | Hib-PRP-T   |
|      | WVTN  |      | ORIMUNE                | Polio-Oral  |
|      | WVTN  |      | Pediarix               | DTAP/Polio/Hep B  |
|      | WVTN  |      | PedvaxHIB              | Hib-OMP   |
|      | WVTN  |      | Plague                 | Plague  |
|      | WVTN  |      | Pneumovax 23           | Pneumococcal 23   |
|      | WVTN  |      | PNU-IMUNE 23           | Pneumococcal 23   |
|      | WVTN  |      | Prevnar 7              | Pneumo-Conjugate  |
|      | WVTN  |      | Prevnar 13             | Pneumococcal conjugate vaccine, 13 valent               |
|      | WVTN  |      | ProHIBit               | Hib-PRP-D   |
|      | WVTN  |      | RabAvert               | Rabies-IM   |
|      | WVTN  |      | Recombivax Peds        | HepB-Peds   |
|      | WVTN  |      | Recombivax-Adult       | HepB-Adult  |
|      | WVTN  |      | Recombivax-Dialysis    | HepB-Dialysis 4 dose                                    |
|      | WVTN  |      | Rho(D)Full             | Rho(D)Full  |
|      | WVTN  |      | Rho(D)IV               | Rho(D)IV  |
|      | WVTN  |      | Rho(D)Mini             | Rho(D)Mini  |
|      | WVTN  |      | RIg                    | RIg   |
|      | WVTN  |      | RIg-HT                 | RIg-HT  |
|      | WVTN  |      | Rotarix                | Rotavirus, monovalent live                              |
|      | WVTN  |      | RotaShield             | Rotavirus tetravalent live oral (removed on 10/16/1999) |
|      | WVTN  |      | RotaTeq                | Rotavirus pentavalent (after 02/02/2006)                |
|      | WVTN  |      | RSV-IgIM               | RSV-IgIM  |
|      | WVTN  |      | RSV-IgIV               | RSV-IgIV  |
|      | WVTN  |      | Rubella                | Rubella   |
|      | WVTN  |      | Td                     | Td  |
|      | WVTN  |      | Tetramune              | DTP-Hib   |
|      | WVTN  |      | Tlg                    | Tlg   |
|      | WVTN  |      | TriHIBit               | DTaP-Hib  |
|      | WVTN  |      | Tripedia               | DTaP  |

| Type | Table | Name | Value                           | Description                  |
|------|-------|------|---------------------------------|------------------------------|
|      | WVTN  |      | TT                              | Tetanus                      |
|      | WVTN  |      | Twinrix                         | HepA-HepB Adult              |
|      | WVTN  |      | Typhim Vi                       | Typhoid-ViCPs                |
|      | WVTN  |      | Typhoid                         | Typhoid-HP                   |
|      | WVTN  |      | Typhoid-AKD                     | Typhoid-AKD                  |
|      | WVTN  |      | Vaccinia (smallpox),<br>diluted | Vaccinia (smallpox), diluted |
|      | WVTN  |      | Vaccinia immune globulin<br>VIG | Vaccinia immune globulin VIG |
|      | WVTN  |      | VAQTA-Adult                     | HepA-Adult                   |
|      | WVTN  |      | VAQTA-Peds 2 Dose               | HepA-Ped 2 Dose              |
|      | WVTN  |      | VAQTA-Peds 3 Dose               | HepA-Peds                    |
|      | WVTN  |      | Varivax                         | Varicella                    |
|      | WVTN  |      | Vivotif Berna/Ty21a             | Typhoid-Oral                 |
|      | WVTN  |      | VZIg                            | VZIg                         |
|      | WVTN  |      | YF-VAX                          | Yellow Fever                 |
|      | WVTN  |      | Zostavax                        | Zoster, live                 |

## CPT Codes (WCPT) and CVX Codes (292)

| CPT                         | CVX | Group      | Vaccine                               | Trade Name                 | Description  | MFG |
|-----------------------------|-----|------------|---------------------------------------|----------------------------|--|-----|
| 90476                       | 54  | Adeno      | Adeno T4                              | Adeno T4                   | Adenovirus type 4, live oral                         | WAL |
| 90477                       | 55  |            | Adeno T7                              | Adeno T7                   | Adenovirus type 7, live oral                         | WAL |
|                             | 82  |            | Adeno, NOS                            |                            | Recorded as CVX 54                                   |     |
| 90581                       | 24  | Anthrax    | Anthrax                               | Anthrax                    | Anthrax  | MIP |
| 90585                       | 19  | BCG        | BCG-TB                                | BCG-TB                     | Bacillus Calmette-Guerin TB                          | OTC |
| 90586                       |     |            | BCG-BC                                | BCG-BC                     | Bacillus Calmette-Guerin bladder cancer              | OTC |
| 90728                       |     |            | BCG, NOS                              |                            | BCG, NOS   |     |
| 90725                       | 26  | Cholera    | Cholera-Injectable                    | Cholera-I                  | Cholera injectable                                   | CHI |
| 90592                       |     |            | Cholera-Oral                          | Cholera-O                  | Cholera Oral   | CHI |
| 90719                       |     | Diphtheria | Diphtheria                            | Diphtheria                 | Diphtheria   | PD  |
| 90700                       | 20  | DTP/aP     | DTaP                                  | Acel-Imune                 | Diphtheria, tetanus, acellular pertussis             | WAL |
|                             |     |            |                                       | Certiva                    |  | BAH |
|                             |     |            |                                       | Infanrix                   |  | SKB |
|                             |     |            |                                       | Tripedia                   |  | PMC |
| 90701                       | 01  |            | DTP                                   | DTP                        | Diphtheria, tetanus, whole cell pertussis            | PMC |
| 90702                       | 28  |            | DT                                    | DT                         | Diphtheria tetanus pediatric                         | PMC |
| 90720                       | 22  |            | DTP-Hib                               | Tetramune                  | DTP – Hib combination                                | WAL |
| 90721                       | 50  |            | DTaP-Hib                              | TriHIBit                   | DtaP-Hib combination                                 | PMC |
| 90723                       | 110 |            | DTAP-HepB-Polio                       | Pediarix                   | DTAP-HepB-Polio combination                          | SKB |
| 90698                       | 120 |            | DTAP-Hib-IPV                          | Pentacel                   | DTAP-Hib-Polio combination                           | PMC |
| 90696                       | 130 |            | DTAP-IPV                              | KINRIX                     | DTAP-Polio combination                               | SKB |
|                             | 106 |            | DTAP, 5 pertussis antigens            | DAPTACEL                   | Diphtheria, tetanus, acellular pertussis, 5 antigens | PMC |
|                             | 107 |            | DTaP, NOS                             |                            | Recorded as CVX 20                                   |     |
| 90655                       | 140 | Influenza  | Influenza, Preservative-Free          | Afluria, Preservative Free | Influenza preservative free                          | CSL |
| Fluvirin, Preservative Free |     |            |                                       | CHI                        |  |     |
| Fluzone Preservative free   |     |            |                                       | PMC                        |  |     |
| Afluria, Preservative Free  |     |            |                                       | CSL                        |  |     |
| Agriflu                     |     |            |                                       | NOV                        |  |     |
| Fluarix                     |     |            |                                       | SKB                        |  |     |
| Flurivin, Preservative Free |     |            |                                       | CHI                        |  |     |
| Fluzone, Preservative Free  |     |            |                                       | PMC                        |  |     |
| 90657                       | 141 | Influenza  | Influenza                             | Afluria                    | Influenza split virus                                | CSL |
|                             |     |            |                                       | Flu-Immune                 |  | WAL |
|                             |     |            |                                       | Flu-Shield                 |  | WAL |
|                             |     |            |                                       | FluLaval                   |  | PMC |
|                             |     |            |                                       | Fluogen                    |  | PD  |
|                             |     |            |                                       | Fluvirin                   |  | CHI |
|                             |     |            |                                       | Fluzone                    |  | PMC |
|                             |     |            |                                       | Afluria                    |  | CSL |
|                             |     |            |                                       | Flu-Immune                 |  | WAL |
|                             |     |            |                                       | Flu-Shield                 |  | WAL |
|                             |     |            |                                       | FluLaval                   |  | PMC |
|                             |     |            |                                       | Fluogen                    |  | PD  |
|                             |     |            |                                       | Fluvirin                   |  | CHI |
|                             |     |            |                                       | Fluzone                    |  | PMC |
| 90659                       | 16  |            | Influenza, Whole virus                |                            | Influenza whole virus                                |     |
| 90660                       | 111 |            | Flu-nasal                             | Flu-Mist                   | Influenza live, for intranasal use                   | WAL |
| 90662                       | 135 |            | Influenza High-Dose Preservative Free | Fluzone High-Dose          | High-Dose Preservative Free                          | PMC |
| 90724                       | 88  |            | Influenza, NOS                        | Flu-Deleted                | Influenza, NOS                                       |     |
|                             |     |            |                                       |                            |  |     |

|       |     |             |  |   |  |            |
|-------|-----|-------------|--|---|--|------------|
| 90663 | 125 | Flu H1N1-09 | Novel Influenza-H1N1-09, nasal           | H1N1 Flu-Nasal                            | Novel Influenza-H1N1-09, nasal                               | MED        |
|       | 126 |             | Novel Influenza-H1N1-09, preserve-free   | H1N1 Afluria, P-free                      | Novel Influenza-H1N1-09, preserve-free                       | CSL        |
|       |     |             |  | H1N1 Fluvirin, P-free                     |  | NOV        |
|       |     |             |  | H1N1 Fluzone, P-free                      |  | PMC        |
|       | 127 |             | Novel Influenza-H1N1-09                  | H1N1 Afluria                              | Novel Influenza-H1N1-09                                      | CSL        |
|       |     |             |  | H1N1 Fluvirin                             |  | NOV        |
|       |     |             |  | H1N1 Fluzone                              |  | PMC        |
|       | 128 |             | Novel Influenza-H1N1-09 all formulations |   | Novel Influenza-H1N1-09 all formulations                     |            |
|       | 128 | Flu H1N1-09 | Novel Influenza-H1N1-09 all formulations | H1N1 Flu-Nasal                            | Novel Influenza-H1N1-09, live virus for nasal administration | MED        |
|       |     |             |  | H1N1 Afluria, P-free                      | Novel Influenza-H1N1-09, preservative –free                  | MED        |
|       |     |             |  | Novel influenza-H1N1-09,-I                | Novel influenza-H1N1-09, injectable                          |            |
| 90632 | 52  | HepA        | HepA adult                               | Havrix adult<br>VAQTA adult               | Hepatitis A adult  | SKB<br>MSD |
| 90633 | 83  |             | HepA ped-2 dose                          | Havrix ped/adol 2 dose<br>VAQTA ped-2     | Hepatitis A pediatric/adolescent 2 dose                      | SKB<br>MSD |
| 90634 | 84  |             | HepA ped-3 dose                          | Havrix ped/adol 3 dose<br>VAQTA ped-3     | Hepatitis A pediatric/adolescent 3 dose                      | SKB<br>MSD |
| 90636 | 104 |             | HepA-HepB Adult                          | Twinrix                                   | Hepatitis A & Hepatitis B adult                              | SKB        |
| 90730 | 85  | HepB        | Hep A, NOS                               |   | Hep A, NOS   |            |
|       | 31  |             | Hep A-peds, NOS                          |   | Recorded as CVX 85   |            |
| 90636 | 104 |             | HepA-HepB Adult                          | Twinrix                                   | DTAP-HepB-Polio combination                                  | SKB        |
| 90723 | 110 |             | DTAP-HepB-Polio                          | Pediarix                                  | Hep B, NOS   |            |
| 90731 | 45  |             | Hep B, NOS                               |   | Hepatitis B Dialysis 3 dose                                  |            |
| 90740 | 44  |             | Hep B-dialysis 3 dose                    |   | Hepatitis B Dialysis 3 dose                                  | MSD        |
| 90743 | 43  |             | HepB adult                               | Recombivax-Adult<br>Engerix-B-Adult       | Hepatitis B adult dose 1ml                                   | MSD<br>SKB |
| 90744 | 08  |             | HepB pediatric                           | Recombivax-Peds<br>Engerix-B-Peds         | Hepatitis B pediatric/adolescent .5ml                        | MSD<br>SKB |
| 90745 | 42  |             | Hep B, adolescent/high risk infant       |   | Hep B, adolescent/high risk infant                           |            |
| 90746 | 43  |             | HepB adult                               | Recombivax-Adult<br>Engerix-B-Adult       | Hepatitis B adult dose 1ml                                   | MSD<br>SKB |
| 90747 | 44  |             | HepB-dialysis 4 dose                     | Recombivax-dialysis<br>Engerix-B dialysis | Hepatitis B Dialysis 4 dose                                  | MSD<br>SKB |
| 90748 | 51  |             | HepB-Hib                                 | Comvax                                    | HepB-Hib Combination   | MSD        |
|       |     |             | HepB-Unspecified                         |   |  |            |
| 90645 | 47  | Hib         | Hib-HbOC                                 | HibTITER                                  | Hemophilus influenza b HbOC 4 dose                           | WAL        |
| 90646 | 46  |             | Hib-PRP-D                                | ProHIBit                                  | Hemophilus influenza b PRP-D booster                         | PMC        |
| 90647 | 49  |             | Hib-OMP                                  | PedvaxHIB                                 | Hemophilus influenza b OMP 3 dose                            | MSD        |
| 90648 | 48  |             | Hib-PRP-T                                | OmniHib                                   | Hemophilus influenza b PRP-T 4 dose                          | PMC        |
|       |     |             |  | ActHib                                    |  |            |
|       |     |             |  | Hiberix                                   |  | SKB        |
| 90720 | 22  |             | DTP-Hib                                  | Tetramune                                 | DTP – Hib combination  | WAL        |
| 90721 | 50  |             | DtaP-Hib                                 | TriHIBit                                  | DtaP-Hib combination   | PMC        |
| 90737 | 17  |             |  |   | Hib, NOS   |            |
| 90748 | 51  |             | HepB-Hib                                 | Comvax                                    | HepB-Hib Combination   | MSD        |
| 90698 | 120 |             | DtaP-Hib-IPV                             | Pentacel                                  | DtaP-Hib-IPV combination                                     | PMC        |
|       |     |             | Hib-Unspecified                          |   |  |            |
| 90649 | 62  | HPV         | HPV, Quadrivalent                        | Gardasil                                  | Human Papilloma Virus, Quadrivalent                          | MSD        |
| 90650 | 118 |             | HPV, Bivalent                            | Cervarix                                  | Human Papilloma Virus, Bivanet                               | SKB        |
|       | 137 |             | HPV, NOS                                 |   | Human Papilloma Virus  |            |
| 90281 | 86  | Ig          | Ig                                       | Ig  | Ig human   |            |
| 90283 | 87  |             | IgIV                                     | IgIV                                      | Ig IV human  |            |
|       |     |             |  | Flebogamma                                |  |            |
| 90287 | 27  |             | Botulinum-antitoxin                      | Botulinum-antitoxin                       | Botulinum antitoxin equine                                   |            |
| 90288 |     |             | Botulism                                 | BabyBIG                                   | Botulism Immune Globulin                                     |            |
|       |     |             |  | Botulism                                  |  |            |
|       |     |             |  | BIG                                       |  |            |
| 90291 | 29  |             | CMV-IgIV                                 | CMV-IgIV                                  | Cytomegalovirus Ig IV human                                  |            |



|       |     |              |                                   |                        |   |     |
|-------|-----|--------------|-----------------------------------|------------------------|---|-----|
| 90741 | 14  |              | Immune Globulin(ISG)              |                        |   |     |
| 90399 |     |              | Ig                                | Ig                     | Unlisted immune globulin  |     |
| 90296 | 12  |              | Diphtheria-antitoxin              | Diphtheria-antitoxin   | Diphtheria antitoxin, equine  |     |
| 90371 | 30  |              | HBIG                              | HBIG                   | Hepatitis B Ig human  |     |
| 90375 | 34  |              | RIg                               | Rig                    | Rabies Ig human   |     |
| 90376 | 34  |              | RIg-HT                            | RIg-HT                 | Rabies Ig heat treated human  |     |
| 90378 | 93  |              | RSV-IgIM                          | RSV-IgIM               | Respiratory syncytial virus Ig  |     |
| 90379 | 71  |              | RSV-IgIV                          | RSV-IgIV               | Respiratory syncytial virus Ig IV   |     |
| 90384 |     |              | Rho(D)Full                        | Rho(D)Full             | Rho(D)Ig Rhlg human full-dose   |     |
| 90385 |     |              | Rho(D)Mini                        | Rho(D)Mini             | Rho(D)Ig Rhlg human mini-dose   |     |
| 90386 |     |              | Rho(D)IV                          | Rho(D)IV               | Rho(D)Ig Rhlg human IV  |     |
| 90389 | 13  |              | TiG                               | BayTet                 |   |     |
|       |     |              |                                   | TiG                    | Tetanus Ig human  |     |
| 90393 | 79  |              | Vaccinia immune globulin          | Vaccinia-Ig            | VacciniaIg human  |     |
| 90396 | 36  |              | VZIG                              | VZIG                   | Varicella-zoster Ig human   |     |
| 90665 | 66  | Lyme         | Lyme                              | LYMERix                | Lyme disease  | SKB |
| 90735 | 39  | Encephalitis | Japanese encephalitis - SC        | JE-Vax                 | Japanese encephalitis - SC  | JPN |
| 90738 | 134 |              | Japanese encephalitis - IM        | Ixiaro                 | Japanese encephalitis - IM  | INT |
| 90705 | 05  | Measles      | Measles                           | Measles                | Measles live 1964-1974 (Eli Lilly)  | MSD |
|       |     |              |                                   | Attenuvax              | Measles live  | MSD |
| 90708 | 04  |              | Measles-Rubella                   | M-R-VAX                | Measles and rubella live  | MSD |
|       |     |              |                                   | Measles-Rubella (MERU) |   | MSD |
| 90704 | 07  | Mumps        | Mumps                             | Mumps                  |   | MSD |
|       |     |              | Rubella-Mumps, NOS                | MumpsVax               | Mumps 1950-1978   | MSD |
|       |     |              | Mumps                             |                        | Mumps live  | MSD |
| 90709 |     |              | Rubella-Mumps, NOS                | Biavax II              | Rubella and mumps live  | MSD |
|       | 38  |              | Rubella-Mumps                     | Mumps-Rubella (MURU)   | Measles, mumps and rubella live   | MSD |
|       |     |              |                                   | MMR II                 |   | MSD |
| 90707 | 03  | MMR          | MMR                               | MMRV                   | Measles, mumps, rubella, varicella live   | MSD |
| 90710 | 94  |              | MMRV                              | Proquad                | Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use   | MSD |
| 90733 | 32  | Meningo      | Meningococcal MPSV4               | Menomune               | Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W-135 Combined  | PMC |
| 90734 | 114 |              | Meningococcal MCV4P               | Menactra               | Meningococcal Groups (A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine  | PMC |
|       | 136 |              | Meningococcal MCV4O               | Menveo                 | Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine   | NOV |
|       | 147 |              | Meningococcal MCV4                |                        | Meningococcal, MCV4, unspecified formulation(groups A, C, Y and W-135) This CVX should only be used for historical doses of meningococcal conjugate vaccine where the formulation is unknown. |     |
|       | 108 |              | Meningococcal, NOS                |                        | meningococcal vaccine, unspecified formulation  |     |
| 90715 | 115 | Pertussis    | Tdap > 7 Years                    | Boostrix               |   | SKB |
|       |     |              |                                   | ORIMUNE                | Poliovirus OPV live oral  | WAL |
| 90712 | 02  | Polio        | Polio oral                        | IPOL                   | Poliovirus inactivated IPV  | PMC |
| 90713 | 10  |              | Polio injectable                  | Pentacel               | DtaP-Hib-IPV combination  | PMC |
| 90698 | 120 |              | DtaP-Hib-IPV                      | Pediarix               | DTAP-HepB-Polio combination   | SKB |
| 90723 | 110 |              | DTAP-HepB-Polio                   | KINRIX                 | DTAP-Polio combination  | SKB |
| 90696 | 130 |              | DTAP-IPV                          |                        | Polio, NOS  |     |
|       | 89  |              | Polio-Unspecified                 | Plague                 | Plague  | GRE |
| 90727 | 23  | Plague       | Plague                            | PNU-IMUNE23            | Pneumococcal polysaccharide 23 valent   | WAL |
| 90732 | 33  | Pneumo-Poly  | Pneumococcal 23                   | Pneumovax23            |   | MSD |
|       |     |              |                                   | Pprevnar 7             | Pneumococcal conjugate polyvalent   | WAL |
| 90669 | 100 | Pneumococcal | Pneumo-conjugate                  | Pprevnar 13            | Pneumococcal conjugate , 13 valent  | PFR |
| 90670 | 133 |              | Pneumococcal conjugate, 13 valent |                        |   |     |
|       | 109 |              | Pneumococcal-Unspecified          | RabAvert               | Rabies intramuscular  | CHI |
| 90675 | 18  | Rabies       | Rabies-intramuscular              | Imovax Rabies I.M.     |   | PMC |
|       |     |              |                                   | Imovax Rabies I.D.     | Rabies intradermal  | PMC |
| 90676 | 40  |              | Rabies-intradermal                |                        | Rabies not otherwise specified  |     |

|       |     |              |                              |                              |   |            |
|-------|-----|--------------|------------------------------|------------------------------|---|------------|
| 90726 | 90  |              | Rabies-NOS                   | RotaShield                   | Rotavirus tetravalent (before 01/01/2000)   |            |
| 90680 | 74  | Rotavirus    | Rotavirus, Tet               |                              | Rotavirus between 01/02/2000 and 12/31/2004)  |            |
|       | 122 |              | Rotavirus                    | RotaTeg                      | Rotavirus pentavalent (after 01/01/2005)  | MSD        |
|       | 116 |              | Rotavirus, Pent              | Rotarix                      | Rotavirus-monovalent, live  | SKB        |
| 90681 | 119 |              | Rotavirus-monovalent         | Rubella                      | Rubella live  | MSD        |
| 90706 | 06  | Rubella      | Rubella                      | Meruvax II                   | Measles and rubella live  | MSD        |
|       |     |              |                              | Measles-Rubella (MERU)       |   | MSD        |
| 90708 | 04  |              | Measles-Rubella              | M-R-VAX                      | Rubella-Mumps, NOS  | MSD        |
|       |     |              |                              |                              |   |            |
| 90709 |     |              | Rubella-Mumps NOS            | Mumps-Rubella (MURU)         | Rubella and mumps live  | MSD        |
|       | 38  |              | Rubella-Mumps                | Biavax II                    | Vaccinia (Smallpox) dry   | MSD        |
|       |     |              |                              | ACAM2000                     |   | ACA        |
|       |     |              |                              | Dryvax                       |   | WAL        |
|       | 75  | Smallpox     | Smallpox                     | Vaccinia (smallpox), diluted | Vaccinia (smallpox), diluted  |            |
|       | 105 |              | Vaccinia (Smallpox), diluted |                              | Vaccinia (Smallpox), diluted  | PMC<br>MBL |
| 90718 | 09  | Td           | Td                           | Td                           | Tetanus and diphtheria adult  |            |
| 90714 | 113 |              | Td preservative free         | Decavac                      | Td preservative free – CPT code is effective 7/1/2005   | PMC        |
| 90714 | 113 |              | Td preservative free         | Tenivac                      | Td preservative free – CPT code is effective 02/01/2012   | PMC        |
| 90715 | 115 |              | TdaP > 7 Years               | Adacel<br>Boostrix           | TdaP > 7 years  | PMC<br>SKB |
| 90703 | 35  | Tetanus      | Tetanus                      | TT                           | Recorded as CVX 35  |            |
|       | 112 |              | Tetanus Toxoid, NOS          | Vivotif Berna/Ty21a          | Typhoid oral  |            |
| 90690 | 25  | Typhoid      | Typhoid-oral                 | Typhim Vi                    | Typhoid VI capsular polysaccharide  | PMC        |
| 90691 | 101 |              | Typhoid-ViCPs                | Typhoid                      | Typhoid heat and phenol inactivated   |            |
| 90692 | 41  |              | Typhoid-H-P                  | Typhoid-AKD                  | Typhoid acetone-killed, dried (military)  |            |
| 90693 | 53  |              | Typhoid-AKD                  |                              | Typhoid not otherwise specified (after 7/1/2005, no CPT code is associated with this vaccine group) |            |
| 90714 | 91  |              | Typhoid-NOS                  |                              |   | MSD        |
| 90710 | 94  | Varicella    | MMRV                         | MMRV                         | Measles, mumps, rubella, varicella live   | MSD        |
| 90716 | 21  |              | Varicella                    | Varivax                      | Varicella live  | PMC        |
| 90717 | 37  | Yellow Fever | Yellow Fever                 | YF-VAX                       | Yellow Fever  | PMC        |
| 90736 | 121 | Zoster       | Zoster (shingles), live      | Zostavax                     | Zoster (shingles), live   | MSD        |